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ABSTRACT
Background
Sustained lymph stagnation engenders a pathological response that is complex and not well
characterized. Tissue inflammation in lymphedema may reflect either an active or passive
consequence of impaired immune traffic.
Methods and Findings
We studied an experimental model of acute post-surgical lymphedema in the tails of female
hairless, immunocompetent SKH-1 mice. We performed in vivo imaging of impaired immune
traffic in experimental, murine acquired lymphatic insufficiency. We demonstrated impaired
mobilization of immunocompetent cells from the lymphedematous region. These findings
correlated with histopathological alterations and large-scale transcriptional profiling results. We
found intense inflammatory changes in the dermis and the subdermis. The molecular pattern in
the RNA extracted from the whole tissue was dominated by the upregulation of genes related
to acute inflammation, immune response, complement activation, wound healing, fibrosis, and
oxidative stress response.
Conclusions
We have characterized a mouse model of acute, acquired lymphedema using in vivo
functional imaging and histopathological correlation. The model closely simulates the volume
response, histopathology, and lymphoscintigraphic characteristics of human acquired
lymphedema, and the response is accompanied by an increase in the number and size of
microlymphatic structures in the lymphedematous cutaneous tissues. Molecular character-
ization through clustering of genes with known functions provides insights into processes and
signaling pathways that compose the acute tissue response to lymph stagnation. Further study
of genes identified through this effort will continue to elucidate the molecular mechanisms and
lead to potential therapeutic strategies for lymphatic vascular insufficiency.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e254 1114
PLoS MEDICINEIntroduction
Acquired lymphedema is a common, important, and often
devastating consequence of successful surgical and adjuvant
therapy of breast cancer and other malignancies [1,2]. The
biology of regional lymphatic vascular insufﬁciency (lymphe-
dema) is complex and, as yet, poorly understood. Conse-
quently, there is a paucity of effective treatment strategies in
patients with lymphedema [2]. There is an obvious need for
better molecular characterization of this disease process to
elucidate the pathobiology of lymphatic vascular insufﬁ-
ciency.
The tissue response to lymph stagnation is rather complex.
The profound structural and functional abnormalities in the
lymphedematous tissues reﬂect a multicellular response to
impaired extracellular ﬂuid mobilization [3]. It has been
suggested that lymphedema provokes an inﬂammatory tissue
response in the skin [4]. While it is conceivable that the
inﬂammatory nature of the tissue response to lymph
stagnation reﬂects either the active or passive consequences
of impaired immune trafﬁc [5], direct experimental con-
ﬁrmation is lacking.
Transcriptional proﬁling has been utilized in the molecular
characterization of isolated lymphatic endothelia [6,7], but
the molecular end-organ response to lymph stagnation
remains unaddressed and poorly understood. While lym-
phatic and blood vessel responses to injury might be
predictable, an elucidation of whole tissue response to
disease is likely to provide more relevant insights into the
important interactions between the tissue matrix and the
resident, heterogeneous cellular populations that likely
compose the target-organ response to persistent lymph
stagnation.
To investigate tissue responses to lymphatic vascular
insufﬁciency, we have undertaken dynamic, in vivo imaging
of the impaired immune trafﬁc in a murine model of
acquired lymphatic insufﬁciency that is intended to simulate,
in part, the lymphatic dysfunction of post-surgical lymphe-
dema [8]. These observations were correlated with an assess-
ment of the cutaneous histopathology in the lymphedema
tissue. Furthermore, to investigate the molecular mechanisms
of tissue response to lymphatic vascular insufﬁciency, we have
undertaken a large-scale transcriptional proﬁling of the
lymphedema tissue utilizing a comprehensive mouse cDNA
microarray containing 42,300 features, representing over
25,000 unique genes and expressed sequence tags (ESTs) [9].
The patterns of gene expression in lymphedema were
contrasted with those observed in normal and surgical sham
controls.
Methods
This study was approved by the Administrative Panels on
Laboratory Animal Care of Stanford University.
Creation of Experimental Lymphedema
Post-surgical lymphedema was experimentally created in
the tails of female hairless, immunocompetent SKH-1 mice
(Charles River Laboratories, Boston, Massachusetts, United
States). Prior to surgery, the mice were anesthetized with
intraperitoneal injection of 0.07 cc of a solution containing
ketamine, xylazine, and saline. For each intervention, the skin
of the tail was circumferentially incised proximally, at a point
16 mm distal to its base. The major lymphatic trunks were
identiﬁed through subcutaneous injection of methylene blue
distal to the surgical incision, followed by controlled, limited
cautery ablation of these structures. In surgical controls
(sham animals), skin incision alone was performed, with
methylene blue injection but without lymphatic cautery. The
normal control animals did not undergo any surgical
manipulation. All animal subjects were sacriﬁced on day 14
of observation. After sacriﬁce, 0.5-gm sections of the tail were
harvested for parafﬁn embedding and RNA extraction.
Tail Volume Quantitation
Tail volume was quantitated in each animal subject
immediately prior to sacriﬁce. Volumetric assessment was
performed with a manually adjusted caliper, with serial
measurement of the tail circumference at 5-mm intervals
along its axis. The tail volume was quantitated with the
truncated cone formula [10].
Histology
Immediately following sacriﬁce, 0.5-gm sections of the tail
were harvested for histological analysis and RNA extraction.
Sections extended from a point 4 mm proximal to the
surgical incision to 8 mm beyond it. For examination of the
responses remote from the point of injury, sections were
harvested 4 cm distal to the surgical site. The specimens were
ﬁxed overnight in 4% paraformaldehyde. After parafﬁn
embedding, 5-lm sections were stained with hematoxylin
and eosin (Richard-Allan Scientiﬁc, Kalamazoo, Michigan,
United States). For visualization of histiocytes/mast cells, the
sections were stained with a 1% toluidine blue solution
(LabChem, Pittsburgh, Pennsylvania, United States) diluted in
1% NaCl. After deparafﬁnization in xylene, sections were
rehydrated though a series of graded alcohol steps starting
with 100% EtOH and ending in 50% EtOH. Slides remained
in toluidine blue for 2 min and were then dehydrated through
graded alcohol washes and covered with Cytoseal (Richard-
Allan Scientiﬁc).
LYVE-1 Immunohistochemical Staining
Parafﬁn sections 5 lm thick were deparafﬁnized in xylene,
rehydrated in a graded series of ethanol, pretreated with
target retrieval solution (Dako, Carpinteria, California,
United States) in a pressure cooker, and incubated in a
peroxidase block for 10 min. Sections were then incubated
with rabbit polyclonal anti-LYVE-1 antibody (1:200, Upstate
Cell Signaling Solutions, Lake Placid, New York, United
States) for 1 h at room temperature, followed by horseradish-
peroxidase-conjugated secondary antibody for 30 min at
room temperature and detection with DAB for 4 min
(Envision System Kit, Dako). Tissue sections were counter-
stained with Gill 1 hematoxylin (Richard-Allan Scientiﬁc) for
15 s, then dehydrated in graded ethanol and coverslipped
with CoverSafe (American Master*Tech Scientiﬁc, Lodi,
California, United States).
Functional Imaging of Immune Traffic in the
Lymphedema Model
Experimental lymphedema was created surgically in the
tails of FVB/N female wild-type mice (Jackson Laboratory, Bar
Harbor, Maine, United States; n ¼ 3), using the technique
described above. Surgical sham controls (n ¼ 5) were also
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bioluminescence imaging, spleens from transgenic luciferase
(luc
þ) heterozygous animals were put into single-cell suspen-
sion, expressing ﬁreﬂy luc under the control of a chicken
beta-actin promoter as previously described [11,12]. The
single-cell suspensions from mouse spleens consisted of
different hematopoietic lineages: ;40% were CD19þ B cells,
;20% were CD4þT cells, ;10%–15% were CD8þT cells, 3%
were NK1.1þ NK cells, and the rest were GR.1þ granulocytes,
Mac-1þ macrophages, CD11cþ dendritic cells, and rarer cell
populations. A total of 4310
6 splenocytes (.97% CD45þ)i n
PBS were injected in a volume of 20 ml into the tail
interstitium, 1 cm caudal to the site of surgery, in both
lymphedema mice and surgical shams. Normal mice were
injected at the corresponding level of the tail. Injections were
performed on post-surgical day 7. Thereafter, luc
þ cells were
repetitively imaged in vivo, at predetermined intervals
following the cell injections. In brief, mice were anesthetized
by intraperitoneal co-injection of a mixture of ketamine (1
mg/mouse), xylazine (lg/mouse) in PBS, and the substrate
luciferin (150 mg/kg).
Ten minutes thereafter, dorsal images were obtained with
an IVIS100 CCD imaging system (Xenogen, Alameda, Cal-
ifornia, United States). The efﬁciency of cellular lymphatic
drainage was determined by direct imaging of light emission
at each of the measured time points, with quantitation of the
change in light emission relative to that observed 20 h after
cell injection, which was deﬁned as 100%.
Microsphere Quantitation of Arterial Perfusion of the
Mouse Tail
The arterial perfusion of the tails of experimental and
control mice was quantitated through intracardiac micro-
sphere injection. After induction of general anesthesia,
stable-labeled 15-lm microspheres (STERIspheres Gold,
BioPAL, Worcester, Massachusetts, United States) were
injected into the left ventricle. Each animal subject received
0.5 3 10
6 microspheres (0.2 ml) injected directly into the left
ventricle. The animals were sacriﬁced after 12 min. The tails
were harvested and dried overnight at 70 8C. The assay to
quantitate disintegrations per minute (dpm) was performed
by BioPhysics Assay Laboratory (Worcester, Massachusetts,
United States) as previously described [13].
Lymphoscintigraphy in Experimental Lymphedema
Whole body lymphoscintigraphy was performed after the
intradermal injection of 100 lCi/0.02 ml of ﬁltered
99mTc-
sulfur colloid (100 nm size) into the tip of the tail. Dynamic
and static images (255 3 255) were acquired using a parallel
hole collimator in a microSPECT gamma camera (Lumigem,
Gamma Medica, Northridge, California, United States). The
dynamic images (1,000 frames; 0.5 s/frame) were started 60 s
prior to the injection of the tracer. The injection lasted for 20
s. The static images (10 min) were acquired immediately after
the dynamic acquisition.
Microarray Experimental Design, RNA Preparation, and
Hybridization
Tissues were derived from nine mice for each of the three
biological states under study (cutaneous specimens from
normal, lymphedematous, and surgical sham animals), for a
total of 27 mice. All microarray hybridizations were
performed with three biological replicates, using pooled
samples independently derived from three mice each, for a
total of nine hybridizations. After tissue was harvested for
histological examination, the remaining, distal portion of the
tail was retrieved for RNA isolation. After completely
separating the tail skin from the cartilage by blunt dissection,
the tissue was separated into segments of 0.5 mm for further
processing. Total RNA was isolated using a modiﬁed two-step
puriﬁcation protocol as described previously [14]. RNA
integrity was assessed using the Agilent 2100 Bioanalyzer
System with RNA 6000 Pico LabChip Kit (Agilent, Palo Alto,
California, United States). First-strand cDNA was synthesized
from 15 lg of total RNA derived from each pool and from
whole embryonic-day-17.5 embryo for reference RNA, in the
presence of Cy3 and Cy5 dUTP, respectively, and hybridized
to the Mouse Transcriptome Microarray [14–16]. A contin-
uously updated and annotated list of the cDNAs included on
this array is available at the Stanford Microarray Database
[17] (Table S1).
Data Acquisition, Analysis, and Statistical Analysis
Image acquisition of the mouse cDNA microarrays was
performed on an Agilent G2565AA Microarray Scanner
System. Feature extraction was performed with GenePix 4.0
software (Bucher Biotec, Basel, Switzerland). Numerical raw
data were migrated from GenePix, without processing, into
an Oracle relational database (CoBi) that was designed
speciﬁcally for microarray data analysis (GeneData, Basel,
Switzerland). The data were then analyzed using Expressionist
software (GeneData). After background subtraction and dye
normalization, features with low signal intensity in the
reference channel were ﬁltered if signal was less than 2.53
background value, retaining a total of 8,353 features for
further analysis. K-nearest-neighbor algorithm was applied to
impute for missing values (,7% of remaining data) [18]. For
two-group comparisons, we used the signiﬁcance analysis of
microarrays (SAM) algorithm [19,20]. Heat maps were
generated using HeatMap Builder [21,22]. For enrichment
analysis we used the EASE analysis software, which uses Gene
Ontology (GO) annotation and Fisher’s exact test to derive
biological themes within particular gene sets [23].
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed
as described [14]. Primers and probes for ten representative
differentially expressed genes were obtained from Applied
Biosystems Assays-on-Demand (Applied Biosystems, Foster
City, California, United States. cDNA was synthesized from 5
lg of total RNA using Taqman Reverse Transcription
Reagents (Applied Biosystems), a set which includes Multi-
Scribe reverse transcriptase, RNase inhibitor, dNTP mixture,
oligo d(T)16, random hexamers, 103 RT buffer, and MgCl2
solution. Ampliﬁcation was performed in triplicate at 50 8C
for 2 min and 95 8C for 10 min, followed by 40 cycles of 95 8C
for 15 s and 60 8C for 1 min. Reactions without template and/
or enzyme were used as negative controls. 18S ribosomal RNA
was used as an internal control. A standard curve derived
from embryonic-day-17.5 mouse RNA was plotted for each
target gene by linear regression using SPSS version 11.0
software (Applied Biosystems). RNA quantity was expressed
relative to the corresponding 18S control. Fold differences
were calculated by dividing the experimental results by the
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primers and probes utilized in this study are listed in Tables 1
and 2.
Results
Murine Model of Acute Experimental Lymphedema: Tail
Volume Quantification
Forty-ﬁve 3-wk-old SKH-1 hairless mice were studied in
this investigation. Of these, 18 underwent post-surgical
lymphatic ablation, nine served as surgical sham controls,
and the remaining 18 served as normal controls. Tail volume
for each group of animals is depicted in Figure 1. At post-
surgical day 7, the lymphedema tail volumes were 200% 6
50% of baseline (p , 0.008 when compared to surgical sham
controls). In the animals subjected to lymphatic ablation, the
edematous enlargement of the tails persisted until the day of
sacriﬁce (day 14). Of note is the fact that cutaneous healing of
the wound, both in the lymphedematous and surgical sham
subjects, was complete by day 14. There was no statistically
signiﬁcant change in tail volume in either surgical sham or
normal controls.
Histological Assessment of the Cutaneous Response to
Lymphatic Interruption
Hematoxylin and eosin specimens derived from the
lymphedematous tails were characterized by the presence of
marked acute inﬂammatory changes (Figure 2B), when
compared to the tissue derived from the normal tails (Figure
2A). There was a notable increase in cellularity, with an
increase in the number of observed ﬁbroblasts and histio-
cytes, as well as a large inﬁltration of neutrophils Granulation
tissue was observed closer to the center of the section, with
bystander destruction of muscle tissue. In addition, there was
hyperkeratosis and spongiosis and edema of the epidermis,
with irregularity of the epidermal/dermal junction, elonga-
tion of the dermal papillae, and a 2- to 3-fold expansion of
tissue between the bone and the epidermis. Lymphedema
specimens were characterized by the presence of numerous
dilated lymphatics in the dermis and subdermis, as seen in
Figure 2B. In contrast, normal tail sections were devoid of
these dilated structures. The normal tissues were character-
ized by the presence of a thin dermis and epidermis, with a
normal epidermal/dermal junction (Figure 2A). The surgical
sham controls were indistinguishable from normals, with no
increased cellularity in dermis or epidermis, and no enlarged
nuclei or hyperkeratosis.
In order to assess whether the lymphedematous changes
created a uniform pathological response distal to the point of
lymphatic ablation, the tissues were also sampled distally (4
cm distal to the point of surgical incision) in normal (Figure
2C) and lymphedematous (Figure 2D) tails. The observed
changes were comparable to those observed adjacent to the
surgical site: lymphedematous tissues were characterized by
hypercellularity, inﬂammatory inﬁltration, and microlym-
phatic dilatation that were not present in the normal tissues.
Quantitative Assessment of Arterial Perfusion in the
Murine Tail Lymphedema Model
While we took great care to avoid concurrent injury to
adjacent vascular structures during surgical lymphatic abla-
tion, we have undertaken an evaluation to exclude inadver-
tent arterial injury during surgery. The mouse tails remained
grossly stable throughout the post-surgical observation phase,
with no evidence of frank necrosis distal to the surgical site.
In order to further substantiate the absence of an arterial
ischemic contribution to the histological pathology observed
in lymphedema, quantitative assessment of arterial perfusion
was performed through intracardiac injection of stable 15-lm
microspheres into the left ventricles of normal (n ¼ 3) and
lymphedema (n ¼ 3) mice. Perfusion of the tail, measured in
disintegrations per minute (dpm), did not differ statistically
between the two categories (normal, 151,186 6 69,213 dpm;
sham, 95,581 6 48,003 dpm), conﬁrming preservation of
arterial supply in the lymphedema animals.
LYVE-1 Immunohistochemical Staining
The nature of the lymphatic vascular response distal to the
anatomic surgical ablation was assessed with quantitative
assessment of lymphatic vessel number and size by immuno-
histochemical staining for LYVE-1(Figure 3) [24,25]. As
observed in the hematoxylin and eosin sections, lymphedema
was characterized by the presence of numerous dilated
microlymphatic structures in the dermis and subdermis. Mean
lymphatic vessel number was determined by averaging the
number of total lymphatic vessels in all the ﬁelds of each slide
Table 1. Primer/Probe Sequences for the Taqman-Based qRT-PCR
Gene Name Forward Primers Reverse Primers Taqman Probes
calgranulin A GACTTCAAGAAAATGGTCACTACTGAGT TGTCCAATTCTCTGAACAAGTTTTCGA FAM-TCAGTTTGTGCAGAATAT-NFQ
calgranulin B AGACAAATGGTGGAAGCACAGTT CCAGGTCCTCCATGATGTCATTTAT FAM-TTCTCTTTCTTCATAAAGGTTGCC-NFQ
clusterin AGGGCGAAGACAAGTACTACCTT CACCACCACCTCAGTGACA FAM-CCACCGTGACCACCC-NFQ
MMP3 TCCCGTTTCCATCTCTCTCAAGA GGGTACCACGAGGACATCAG FAM-TCCCTCTATGGAACTCC-NFQ
MMP14 CCCAAGGCAGCAACTTCAG CCTGGAGGTAGGTAGCCATACTG FAMCCCGAAGCCTGGCTGC-NFQ
DOI: 10.1371/journal.pmed.0030254.t001
Table 2. Names of Taqman-Based qRT-PCR Probes
Symbol Name Applied Biosystems ID
Cdh11 cadherin 11 Mm00515462_m1
HADH2 hydroxyacyl-coenzyme A
dehydrogenase type II
Mm00840109_m1
Myd88 myeloid differentiation primary
response gene 88
Mm00440338_m1
DOI: 10.1371/journal.pmed.0030254.t002
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Inflammatory Manifestations of LymphedemaFigure 1. Tail Volume Changes at Post-Surgical Day 7 and at Day 14
DOI: 10.1371/journal.pmed.0030254.g001
Figure 2. Histopathology of Experimental Lymphedema in the Murine Tail
Lymphedema was characterized by the presence of marked acute inflammatory changes, both adjacent to the surgical site and within distal regions of
the tail, remote from the site of surgical ablation.
(A) Normal tail skin harvested 16 mm from the base of the tail is characterized by the presence of a thin dermis and epidermis, with a normal epidermal/
dermal junction. Surgical sham controls were indistinguishable from normals, with no increased cellularity in dermis or epidermis, and no enlarged
nuclei or hyperkeratosis.
(B) Lymphedematous skin harvested immediately distal to the site of prior surgical lymphatic ablation is characterized by the presence of marked acute
inflammatory changes, absent in the tissue derived from the normal tails. There is a notable increase in cellularity, with an increase in the number of
observed fibroblasts and histiocytes, as well as a large infiltration of neutrophils. There is hyperkeratosis and spongiosis and edema of the epidermis,
with irregularity of the epidermal/dermal junction, elongation of the dermal papillae, and a 2- to 3-fold expansion of tissue between the bone and the
epidermis. There are numerous dilated lymphatic microvessels in the dermis and subdermis (black arrows). In contrast, normal tail sections were devoid
of these dilated structures.
(C) Normal skin derived from the distal tail. No inflammation, hypercellularity, or lymphatic dilatation is observed.
(D) Distal skin in lymphedema. Spongiosis and lymphatic microvascular dilatation (black arrows) are once again detectable.
DOI: 10.1371/journal.pmed.0030254.g002
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with a lumen were counted as individual lymphatic vessels.
Quantitation was performed for normals (n ¼ 3), surgical
shams (n¼3), and lymphedema tails (n¼3). Lymphedema was
characterized by an increase in LYVE-1-positive vessel
number per ﬁeld that was not observed in shams: lymphede-
ma, 7.0 6 4.8; sham, 0.6 6 0.5; and normal, 1.2 6 0.8.
Vessel area was quantitated according to the formula
p r1 r2. The average lymphatic luminal area per ﬁeld was 503
6 158 lm
2 in normals, 436 6 345 lm
2 in shams, and 51,344 6
18,688 lm
2 in lymphedema. Normals and shams did not differ
statistically, but the lymphedema group displayed a statisti-
cally signiﬁcant increase in average vessel area when
compared either to normals or to sham surgical animals (p
¼ 0.009 for each comparison). Thus, in summary, the
experimental lymphedema is accompanied by an increase in
vessel number and, even more notably, by an increase in
lymphatic vascular cross-sectional area.
Lymphoscintigraphy of Experimental Lymphedema
Whole body lymphoscintigraphy was performed in normal
(n ¼ 4) and lymphedema (n ¼ 4) mice. All non-operated mice
showed lymphatic drainage from the tip of the tail through
two lumbar lymph nodes, asymmetric para-aortic nodes, and
mediastinal nodes with ﬁnal visualization of the liver. The
lymphatic ﬂow speed in basal conditions was estimated to be
0.9 6 0.66 mm/s. In the lymphedema animals, signiﬁcant
dermal backﬂow was present, but no ﬂow was observed
beyond the base of the tail. These lymphoscintigraphic
ﬁndings closely simulate the qualitative changes observed in
the analogous imaging of acquired human lymphedema.
Functional In Vivo Imaging of Immune Traffic
The lymphatic vasculature participates in the immune
response through the continuous transportation of white
blood cells and antigen-presenting cells. The constellation of
histological observations in this model, otherwise unex-
plained by impaired interstitial ﬂuid mobilization, suggests
that derangements in lymphatic immune trafﬁc might
contribute—actively, passively, or both ways—to the biology
of lymph stagnation. Accordingly, we chose to corroborate
histopathology with observed, quantiﬁable changes in im-
mune trafﬁc.
Bioluminescence imaging was performed on days 3, 5, and
7.5 following the introduction of luc
þ cells into the distal tail
(corresponding to post-operative days 10, 12, and 17.5,
respectively). In general, when compared to normals, the
clearance of bioluminescent immunocytes was delayed in
lymphedema, but remained unimpaired in the surgical sham
controls. Figure 4 depicts a series of imaging experiments for
a representative pair of lymphedema and normal control
mice. Relative photon density, expressed as the percent of the
observed value on day 1, was signiﬁcantly greater in
lymphedema than in the normals, both at day 3 and at day
7 post-injection (Figure 4).
Large-Scale Analysis of Cutaneous Gene Expression in
Response to Lymphatic Vascular Insufficiency (Lymph
Stasis)
cDNA microarrays containing a large portion of the mouse
transcriptome were used to study the repertoire of genes
expressed in the murine skin structures. Triplicate micro-
array experiments were performed using pooled RNA from
the tail skin of female SKH-1 hairless mice representing three
biological states: normal, lymphedematous, and surgical
sham. Our analyses demonstrated signiﬁcantly different
patterns of gene expression in normal skin and the skin
derived from lymphedematous mice. SAM, at a false
detection rate (FDR) of 5%, identiﬁed 429 upregulated genes
in the lymphedema state versus 183 downregulated genes
Figure 3. LYVE-1 Immunohistochemical Staining
Immunohistochemical staining for LYVE-1 is depicted in surgical sham controls (A) and in lymphedema (B) (black arrows). The lymphedema response is
characterized by the presence of numerous dilated microlymphatic structures in the dermis and subdermis. Lymphedema produces a statistically
significant increase in average cross-sectional vessel area.
DOI: 10.1371/journal.pmed.0030254.g003
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Inflammatory Manifestations of LymphedemaFigure 4. Dynamic Imaging of Immune Traffic in Experimental Lymphedema
(A) In vivo bioluminescence imaging of immune traffic. Bioluminescence imaging was performed at defined time points following the introduction of
luc
þcells. This figure contains a representative series of imaging experiments for paired normal control (A) and lymphedema (B) mice. Photon densities
range from red (high) to blue (low). In general, clearance of bioluminescent immunocytes from the lymphedematous tails was delayed, but remained
unimpaired in the surgical sham controls. The left panel shows a perceptible increase in photon densities in lymphedema on day 3 post-injection (post-
operative day 10). Within several days, the disparity in cellular clearance is even more evident (middle panel); as late as day 17 post-injection, there is
still visible bioluminescence in the lymphedematous tail, while all activity has cleared from the normal tail (right panel). The original surgical site is
depicted by the white arrows. The black marks on the tail denote 8-mm vertical distances; splenocyte injection was performed 24 mm below the
surgical site.
(B) Quantitative assessment of in vivo bioluminescence imaging of immune traffic. Relative photon density, expressed as a percent of the observed
value on day 1, was significantly greater in lymphedema than in normal controls, both at day 3 and at day 7 post-injection (*, p , 0.05; §, p , 0.02).
DOI: 10.1371/journal.pmed.0030254.g004
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Inflammatory Manifestations of Lymphedema(Figure 5). There were no statistically signiﬁcant differences
between normal mice and surgical control animals (SAM,
FDR , 25%). A complete list of differentially regulated genes
is provided in Tables 3 and 4.
To identify important biological themes represented by
genes differentially expressed in the atherosclerotic lesions,
we functionally annotated the genes using GO terms.
Enrichment analysis with the Fisher’s exact test (EASE
software) demonstrated several statistically signiﬁcant ontol-
ogies (Figure 5; Tables 5 and 6), including several pathways
associated with inﬂammation. The inﬂammatory processes,
such as defense response, immune response, response to
stress, response to pest/pathogen/parasite, and complement
activation, represent both humoral immune response and
innate immunity.
Further scrutiny of the list of genes whose expression is
signiﬁcantly altered in lymphedematous skin suggests that the
disease process can be characterized by alterations within a
relatively small set of functional attributes, as summarized in
Table 7. These processes include acute inﬂammatory
response, wound healing and ﬁbrosis, angiogenesis, cytoske-
letal organization, Wnt pathway activation, and adipogenesis.
qRT-PCR Confirms the Accuracy of Microarray
Hybridization Results
Differential expression of eight representative genes from
various pathways was conﬁrmed by qRT-PCR. The genes were
selected to represent the spectrum of magnitude and
direction of change of lymphedematous gene expression
relative to normal. The genes assayed included calgranulin A,
calgranulin B, matrix metalloproteinase 3 (MMP3), matrix metal-
loproteinase 14 (MMP14), myeloid differentiation primary response
gene 88 (MYD88), hydroxysteroid (17-beta) dehydrogenase 2
(HADH2), cadherin 11, and clusterin. Overall, the results of the
two methods correlated well (Figure 6).
Discussion
In this study, we have characterized a mouse model of
lymphedema using in vivo functional imaging and histopa-
thological correlation. This model of acute, acquired lymph
stagnation closely simulates the volume response, histopa-
thology, and lymphoscintigraphic characteristics of human
acquired lymphedema. LYVE-1 immunohistochemistry dem-
onstrates that this acute impairment of lymph transport is
accompanied by an increase in the number and size of
microlymphatic structures in the lymphedematous cutaneous
tissues.
We have also undertaken molecular characterization of the
disease process through comprehensive transcriptional
proﬁling of the murine lymphedematous tail skin. We have
identiﬁed a set of genes and molecular pathways that play a
role in the unique biology of this cutaneous response to
lymph stasis (lymphedema). Recognition of this molecular
response pattern is likely to enhance our comprehension of
the pathogenesis and biology of lymphedema.
The model has been elaborated to simulate the regional,
acquired lymph stagnation that can arise after trauma,
surgery, and cancer therapeutics [8]. Despite apparent rapid
healing of the external cutaneous wound, the model features
a stable, persistent edematous increase in the volume of the
tail, accompanied by a profound inﬂammatory response;
neither edema nor inﬂammation is seen in surgical controls.
The cutaneous inﬂammatory response observed in this
model replicates clinical descriptions of human acquired
lymphedema, where there is frequently evidence of concom-
Figure 5. SAM Analysis of Microarray Data
At an FDR of 5%, SAM analysis identified 429 upregulated genes in the lymphedema state versus 183 downregulated genes. There were no statistically
significant differences between normal mice and surgical control animals (SAM, FDR , 25%). Enrichment analysis with the Fisher’s exact test (EASE
software) demonstrated several statistically significant ontologies.
DOI: 10.1371/journal.pmed.0030254.g005
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e254 1121
Inflammatory Manifestations of LymphedemaTable 3. Upregulated Genes in Lymphedema versus Normal Control (SAM, FDR , 0.05)
Gene ID Gene
Symbol
LocusLink
Accession ID
Gene Name Score
(d)
a
Fold
Change
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(%)
AV020023 S100a9 20202 S100 calcium binding protein A9 (calgranulin B) 17.47 21.5 0.91
AV171621 Stfa3 20863 stefin A3 14.55 4.3 0.91
AV038429 Rarres2 71660 Mus musculus, similar to RIKEN cDNA 0610007L05 gene,
clone MGC:18838 IMAGE:4212222, mRNA, complete cds
11.98 2.9 0.91
BG072297 Fcer1g 14127 Fc receptor, IgE, high affinity I, gamma polypeptide 11.02 4.2 0.91
AA139015 B2m 12010 beta-2 microglobulin 10.86 3.9 0.91
AV034788 cytotoxic T lymphocyte-associated protein 2 alpha 10.81 4.5 0.91
432238 EST 10.42 3.3 0.91
AV171866 Stfa1 20861 ESTs, highly similar to CTY3 mouse stefin 3 (Mus musculus) 10.04 4.6 0.91
AV068500 Lgals2 107753 lysozyme 10.02 4.6 0.91
AA003942 Tnc 21923; 402769 tenascin C 9.21 7.8 0.91
AV109517 Cyba 13057 cytochrome b-245, alpha polypeptide 8.91 2.6 0.91
W48195 1500040F11Rik 22272 RIKEN cDNA 1500040F11 gene 8.80 1.8 0.91
43822 EST 8.68 2.1 0.91
AW547306 C1qg 12262 complement component 1, q subcomponent, c polypeptide 8.38 2.6 0.91
AV083964 heme oxygenase (decyling) 1 8.12 1.6 0.91
BG073325 EST 8.02 1.3 0.91
AV094691 ubiquitin-conjugating enzyme E2 variant 1 8.01 1.5 0.91
AV114351 Rbp1 19659 retinol binding protein 1, cellular 7.66 2.5 0.91
BG063011 Ctla2a 13024; 13025 cytotoxic T lymphocyte-associated protein 2 alpha 7.54 4.0 0.91
AV069980 B2m 12010 beta-2 microglobulin 7.47 3.2 0.91
AV133727 Ssr4 20832 signal sequence receptor, delta 7.04 1.4 0.91
431201 EST 6.84 2.7 0.91
411130 EST 6.83 2.0 0.91
AV09442 EST, weakly similar to RL 15 rat 60S ribosomal protein L15
(Rattus norvegicus)
6.72 1.7 0.91
AV068190 Ndufa6 67130 M. musculus, similar to hypothetical protein MGC3178,
clone MGC:28887 IMAGE:4911455, mRNA, complete cds
6.58 2.4 0.91
AI118893 S100a8 20201 EST 6.57 16.0 0.91
AW550933 EST, weakly similar to PRP3 mouse proline-rich protein
MP-3 (M. musculus)
6.57 1.3 0.91
AV094499 Isyna1 71780 RIKEN cDNA 1300017C10 gene 6.49 1.6 0.91
AV060165 EST 6.37 3.9 0.91
AV066072 Ifitm3 66141 RIKEN cDNA 1110004C05 gene 6.35 2.1 0.91
432539 EST 6.22 3.8 0.91
AV037118 B2m 12010 beta-2 microglobulin 6.14 3.0 0.91
AV028863 ferritin heavy chain 6.06 2.0 0.91
AV035363 Prg1 19073 proteoglycan, secretory granule 5.98 3.7 0.91
AV013352 1810009M01Rik 65963 RIKEN cDNA 1810009M01 gene 5.94 2.3 0.91
AV054688 Muc1 17829 EST 5.93 1.7 0.91
412016 EST 5.86 3.6 0.91
411315 EST 5.84 1.8 0.91
412595 EST 5.82 1.4 0.91
AV061443 Ifngr1 15979 interferon gamma receptor 5.81 2.0 0.91
BG072156 Ifitm3 66141 RIKEN cDNA 1110004C05 gene 5.78 3.7 0.91
413077 EST 5.73 1.7 0.91
AV035765 EST 5.72 4.5 0.91
AA177689 Mrg2 17537 myeloid ecotropic viral integration site-related gene 2 5.71 1.6 0.91
AA162879 stromal cell-derived factor 1 5.70 2.4 0.91
AV052140 Cxcl12 20315 stromal cell-derived factor 1 5.63 2.0 0.91
AA087526 Rbp1 19659 retinol binding protein 1, cellular 5.59 2.9 0.91
AV109528 myosin light chain, alkali, nonmuscle 5.57 1.7 0.91
AV108847 Gnl2 230737 M. musculus, similar to nucleolar GTPase, clone MGC: 7863
IMAGE: 3501393, mRNA complete cds
5.54 2.3 0.91
BG070106 Lcn2 16819 lipocalin 2 5.47 6.1 0.91
431107 EST 5.41 2.6 1.08
BG073227 Fbln2 14115 fibulin 2 5.41 2.0 1.08
AA072722 Fcer1g 14127 Fc receptor, IgE, high affinity I, gamma polypeptide 5.35 3.0 1.08
412394 EST 5.31 1.7 1.08
BG063844 Lcp1 18826 plastin 2, L 5.29 3.3 1.08
AV087823 Cbr2 12409 carbonyl reductase 2 5.29 1.8 1.08
413592 EST 5.28 2.4 1.08
AV036203 Lsp1 16985 lymphocyte specific 1 5.22 1.7 1.08
AV141619 RIKEN cDNA 1810037I17 gene 5.22 1.4 1.08
BG074642 BC027309 243371 RIKEN cDNA 0610007L05 gene 5.21 2.5 1.08
AV070323 Ndufab1 70316 RIKEN cDNA 2610003B19 gene 5.21 1.7 1.08
AV104403 Ctsz 64138 cathepsin Z 5.17 2.2 1.08
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BG068219 Lgmn 19141 legumain 5.16 2.4 1.08
AV085954 complement component 1, q subcomponent, beta polypeptide 5.15 3.2 1.08
AV058060 Calm1 12313 calmodulin 1 5.15 1.8 1.08
AV087404 2310056P07Rik 70186 RIKEN cDNA 2310056P07 gene 5.09 1.6 1.08
AV094766 M. musculus, similar to aspartyl-tRNA synthetase, clone MGC:6719
IMAGE:3586278, mRNA, complete cds
5.08 2.3 1.08
AV024220 follistatin-like 5.03 3.2 1.08
411275 EST 5.03 2.0 1.08
AV088911 Sh3yl1 24057 S100 calcium binding protein A11 (calizzarin) 4.97 1.6 1.08
AV109524 Cxcl4 56744 platelet factor 4 4.96 1.8 1.08
AV094436 Uqcrc1 22273 ubiquinol-cytochrome c reductase core protein 1 4.96 2.2 1.08
AI875081 Gpx1 14775 glutathione peroxidase 1 4.95 1.9 1.08
AV104473 Ctsz 64138 cathepsin Z 4.92 2.0 1.08
AV093499 Tmsb4x 19241 thymosin, beta 4, X chromosome 4.91 1.7 1.08
AV001464 Grn 14824 granulin 4.90 1.7 1.08
AV087961 Emcn 59308 endomucin 4.88 1.7 1.08
BG074570 myosin light chain, alkali, nonmuscle 4.83 1.5 1.08
AV113890 Fabp5 16592 fatty acid binding protein 5, epidermal 4.81 1.9 1.08
AV133965 Esd 13885 esterase 10 4.81 1.9 1.08
AV084804 Tagln2 21346 M. musculus, similar to transgelin 2, MGC:6300 IMAGE:2654381,
mRNA,complete cds
4.80 1.6 1.08
BG071322 Cbr2 12409 carbonyl reductase 2 4.78 1.6 1.08
AI847496 Snx5 69178 sorting nexin 5 4.78 2.0 1.08
AV093793 ribosomal protein L24 4.76 1.4 1.08
AW556849 EST 4.73 1.5 1.08
AI841291 spermidine/spermine N1-acetyl transferase 4.72 1.5 1.08
411545 EST 4.70 2.7 1.08
BG073274 Gnai2 14678 guanine nucleotide binding protein, alpha inhibiting 2 4.65 1.5 1.08
AV014173 Dnajc13 235567 ESTs, highly similar to T00361 hypothetical protein
KIAA0678 (Homo sapiens)
4.59 1.8 1.36
AV009300 Col4a1 12826 procollagen, type IV, alpha 1 4.54 2.0 1.36
AV010312 Col4a2 12827 procollagen, type IV, alpha 2 4.50 2.0 1.36
BG074937 H2-D1 14964; 14980;
14972; 497653;
15013
histocompatiblility 2, D region locus 1 4.49 2.1 1.36
W14193 S100a9 20202 S100 calcium binding protein A9 (calgranulin B) 4.47 14.9 1.36
AV023779 Sssca1 56390; 17826 Sjogren’s syndrome/scleroderma autoantigen 1
homolog (H. sapiens)
4.47 3.7 1.36
AV086173 Ppib 19035 peptidylprolyl isomerase B 4.41 1.4 1.59
431892 EST 4.40 2.8 1.59
432647 EST 4.39 3.4 1.59
431995 EST 4.39 1.5 1.59
AV095167 Gpx1 14775 glutathione peroxidase 1 4.38 1.7 1.59
AI596034 Ror2 26564; 78531 receptor tyrosine kinase-like orphan receptor 2 4.35 1.7 1.59
411582 EST 4.34 1.3 1.59
BG067559 Ctsc 13032 cathepsin C 4.33 2.3 1.59
AV086001 209294 ESTs, highly similar to CYT3 mouse stefin 3 (M. musculus) 4.33 2.3 1.59
AV171061 Cotl1 72042 coactosin-like protein 4.32 1.3 1.59
BG065250 Ctsh 13036 cathepsin H 4.32 1.5 1.59
AV017041 N-acetylneuraminate pyruvate lyase 4.30 4.1 1.59
AV096227 thymosin, beta 10 4.29 2.5 1.59
411500 EST 4.28 2.7 1.59
AV106608 glutathione peroxidase 1 4.27 1.8 1.59
AV104166 Alox5ap 11690 arachidonate 5-lipoxygenase activating protein 4.25 2.9 1.59
AI325865 Arpc4 68089 actin related protein 2/3 complex, subunit 4 (20 kDa) 4.24 1.5 1.73
BG074171 Stfa1 20861 ESTs, highly similar to CYT3 mouse stefin 3 (M. musculus) 4.24 6.3 1.73
BG075608 Tpi1 21991 triosephosphate isomerase 4.24 1.9 1.73
AV105953 calreticulin 4.23 2.0 1.73
AV094913 1110020C13Rik 66151 RIKEN cDNA 1110020C13 gene 4.22 1.3 1.73
412705 EST 4.22 4.0 1.73
410890 EST 4.21 1.7 1.73
412501 EST 4.21 1.4 1.73
AI526714 Gpx1 14775 glutathione peroxidase 1 4.18 1.8 1.73
AV014751 Lox 16948 lysyl oxidase 4.17 2.7 1.73
BI076685 EST 4.17 1.4 1.73
AV001134 Arhgdib 11857 Rho,GDP dissociation inhibitor (GDI) beta 4.15 1.8 1.73
BG072620 Rps6 20104 ribosomal protein S6 4.14 1.3 1.73
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BG065930 RIKEN cDNA 3110023F10 gene 4.13 1.6 1.73
BG076357 erythroid differentiation regulator 4.11 2.7 1.73
AV094406 M. musculus, clone IMAGE:3499608, mRNA, partial cds 4.11 1.5 1.73
AW554113 EST 4.11 1.5 1.73
411855 EST 4.10 1.5 1.73
AV031220 SET translocation 4.09 1.5 1.96
BG072550 Carhsp1 52502 RIKEN cDNA 120011K09 gene 4.08 1.8 1.96
AV038462 Ctla2a 13024; 13025 cytotoxic T lymphocyte-associated protein 2 alpha 4.07 4.0 1.96
AV120085 ribosomal protein S18 4.06 1.2 1.96
AV009166 capping protein beta 1 4.05 1.7 1.96
412280 EST 4.04 2.9 1.96
AV111409 Ubl5 66177 ubiquitin-like 5 4.02 1.3 1.96
AV039992 Dnajc2 22791 zuotin related factor 2 4.02 1.3 1.96
AW543803 hypoxia inducible factor 1, alpha subunit 4.01 1.9 1.96
AW551760 interferon induced transmembrane protein 3-like 4.00 1.7 1.96
BG071182 0610011I04Rik 66058 RIKEN cDNA 0610011I04 gene 4.00 2.7 1.96
BG065327 Aatf 56321 traube 4.00 1.2 1.96
AW553642 Cald1 109624; 18153 M. musculus, similar to caldesmon 1, clone MGC:30319
IMAGE:5148205, mRNA, complete cds
4.00 2.1 1.96
430643 EST 4.00 3.4 1.96
432671 EST 3.98 1.8 1.96
431125 EST 3.97 2.7 1.96
AV009103 Expressed sequence AA408606 3.96 1.5 1.96
AW554082 EST 3.95 1.8 1.96
AV094414 Slc35b1 73836 M. musculus, clone MGC:31031 IMAGE:5137689, mRNA, complete cds 3.91 2.3 1.96
AV017679 small EDRK-rich factor 2 3.90 1.7 1.96
411766 EST 3.89 1.3 1.96
AV094647 Ndufs8 225887 M. musculus, clone MGC:37950 IMAGE:5132866, mRNA, complete cds 3.89 1.3 2.28
AV105113 Ifitm3 66141 RIKEN cDNA 1110004C05 gene 3.89 1.6 2.28
AF065441 Fgfbp1 14181 fibroblast growth factor binding protein 1 3.87 1.5 2.28
AV065392 Atp6v0b 114143 ESTs 3.87 1.4 2.28
BG063611 lectin, galactose binding, soluble 1 3.86 2.9 2.28
430977 EST 3.86 2.7 2.28
BG072866 M. musculus, clone MGC:28609 IMAGE:4218551, mRNA, complete cds 3.85 1.3 2.28
411576 EST 3.84 2.5 2.28
AV094612 C87860 97112 Expressed sequence C87860 3.83 1.4 2.28
BG075953 Usp33 170822 Vhlh-interacting deubiquitinating enzyme 1 3.83 1.9 2.28
AW548371 EST 3.81 1.7 2.28
432957 EST 3.81 2.1 2.28
AV109529 ferritin heavy chain 3.81 2.2 2.28
AV109316 thymosin, beta 4, X chromosome 3.81 1.7 2.28
433177 EST 3.80 1.6 2.28
413039 EST 3.80 1.8 2.28
AV070066 EST 3.78 1.5 2.28
AV294875 Pgk1 18655 phosphoglycerate kinase 1 3.78 1.7 2.28
BG072801 S100a9 20202 S100 calcium binding protein A9 (calgranulin B) 3.78 19.2 2.28
AV014493 Zbtb17 22642 zinc finger protein 100 3.78 1.6 2.28
413454 EST 3.77 4.5 2.28
BG075853 Sepp1 20363 selenoprotein P, plasma 1 3.77 2.8 2.28
AV087234 Eef2k 13631; 436008 Expressed sequence C86191 3.76 1.7 2.28
AV028503 Sat1 20229 spermidine/spermine N1-acetyl transferase 3.76 1.6 2.73
AV133930 Hexa 15211 hexosaminidase A 3.74 2.0 2.73
410654 EST 3.74 2.7 2.73
AV025941 aquaporin 1 3.74 2.0 2.73
AV050073 S100a9 20202 S100 calcium binding protein A9 (calgranulin B) 3.74 22.5 2.73
AV093600 Atp5j2 57423 ATP synthase, H
þ transporting, mitochondrial F0 complex,
subunit f, isoform 2
3.73 1.6 2.73
AA408841 Csrp1 13007 cystein rich protein 3.73 1.7 2.73
AW553287 osteoblast specific factor 2 (fasciclin I-like) 3.72 2.1 2.73
AV043279 cholinergic receptor, nicotinic, epsilon polypeptide 3.71 1.6 2.73
AV134223 fatty acid binding protein 5, epidermal 3.70 2.2 2.73
BG063873 Ftl1 14325 ferritin light chain 1 3.70 2.4 2.73
AV134053 Rpo1–3 20018 RNA polymerase 1–3 (16-kDa subunit) 3.70 1.2 2.73
AW547223 ribosomal protein L29 3.68 2.5 2.73
BG064350 actinin, alpha 1 3.66 1.8 2.73
AV113595 embryonic ectoderm development 3.65 1.9 2.73
AV094967 Cox6b1 110323 RIKEN cDNA 2010000G05 gene 3.65 1.4 2.73
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AV072373 RIKEN cDNA 2510010F10 gene 3.63 2.3 2.73
AV094998 Loxl1 16949; 78901 lysyl oxidase-like 3.63 1.8 2.73
AV012373 Tagln 21345 transgelin 3.62 1.5 2.73
AA162273 Col4a1 12826 procollagen, type IV, alpha 1 3.62 3.0 2.73
BG065103 Ly6e 17069 lymphocyte antigen 6 complex, locus E 3.61 1.5 2.73
BG071626 ESTs, Moderately similar to glyceraldehyde 3-phosphate
dehydrogenase (M. musculus)
3.60 1.5 3.17
BG074224 ESTs 3.60 1.4 3.17
AV000846 Sod2 20656 superoxide dismutase 2, mitochondrial 3.58 1.5 3.17
AV030230 5330438D12Rik 327824 ESTs 3.57 2.2 3.17
AA980714 Pecam1 18613 platelet/endothelial cell adhesion molecule 3.56 2.0 3.17
AV162332 RIKEN cDNA 3110001M13 gene 3.55 2.3 3.17
412441 EST 3.55 1.8 3.17
AV031080 Ubl3 24109 ubiquitin-like 3 3.55 1.9 3.17
AV030853 D8Ertd325e 66855 RIKEN cDNA 1100001J13 gene 3.54 1.5 3.17
AV094526 Rps6kl1 238323 M. musculus, hypothetical protein MGC11287 similar to
ribosomal protein S6 kinase, clone MGC:28043 IMAGE:3672127,
mRNA, complete cds
3.54 1.2 3.17
AV133784 Cald1 109624; 18153 M. musculus, similar to caldesmon 1, clone MGC:30319
IMAGE:5148205, mRNA, complete cds
3.53 1.9 3.17
C79946 Expressed sequence C79946 3.52 1.7 3.17
AA086550 Mrg2 17537 myeloid ecotropic viral integration site-related gene 2 3.52 1.6 3.17
AW550650 Tctex1 21648 t-complex testis expressed 1 3.51 1.8 3.17
AV070981 hypoxia inducible factor 1, alpha subunit 3.50 1.5 3.17
BG073809 Bgn 12111 biglycan 3.49 2.6 3.17
BG071407 Mdh2 17448 malate dehydrogenase, mitochondrial 3.49 1.5 3.17
AV028607 Serpini1 20713 serine (or cysteine) proteinase inhibitor, clade I
(neuroserpin), member 1
3.48 1.9 3.17
AV006041 2900073G15Rik 67268 RIKEN cDNA 2900073G15 gene 3.48 1.6 3.17
412701 EST 3.48 1.4 3.17
AV103730 Arpc3 56378 actin related protein 2/3 complex, subunit 3 (21 kDa) 3.48 1.7 3.17
AV109544 Map1lc3b 67443 microtubule-associated protein 1 light chain 3 3.48 1.3 3.17
AV030400 myosin light chain, alkali, nonmuscle 3.45 1.7 3.17
432209 EST 3.45 2.0 3.17
AV114184 H2-Bf 14962 histocompatibility 2, complement component factor B 3.43 3.1 3.24
BG067257 Clta 12757 clathrin, light polypeptide (Lca) 3.41 1.4 3.24
BG070050 Map1lc3b 67443 microtubule-associated protein 1 light chain 3 3.41 1.3 3.24
AV017254 Mpp1 17524 membrane protein, palmitoylated (55 kDa) 3.40 1.9 3.24
AV093759 Rps12 20042 ribosomal protein S12 3.40 1.5 3.24
AI841252 Tmem4 56530 transmembrane protein 4 3.39 1.4 3.24
AV006536 EST 3.38 1.3 3.24
AV094757 EST 3.37 2.0 3.24
AV055121 Sepx1 27361 selenoprotein R 3.36 1.6 3.24
BG073062 Atp5j2 57423 ATP synthase, H
þ transporting, mitochondrial F0 complex,
subunit f, isoform 2
3.36 1.5 3.24
AU043587 Map17 67182 membrane-associated protein 17 3.35 1.5 3.24
AV087816 Krt1–14 16664 keratin complex 1, acidic, gene 14 3.34 1.4 3.24
AV074746 thymosin, beta 4, X chromosome 3.34 1.7 3.24
AV087388 0910001A06Rik 223601 M. musculus, similar to hypothetical protein DKFZp566A1524,
clone MGC:18989 IMAGE:4012217, mRNA, complete cds
3.33 2.1 3.24
BG065030 Gpx1 14775 glutathione peroxidase 1 3.33 1.5 3.24
BG071424 Itm2c 64294 integral membrane protein 3 3.33 1.3 3.24
AV133758 432633 phosphoglycerate kinase 1 3.33 2.3 3.24
BG075599 Mpp1 17524 membrane protein, palmitoylated (55 kDa) 3.31 1.4 3.24
AV094520 Htf9c 15547 Hpall tiny fragments locus 9c 3.31 1.5 3.24
BG064704 lectin, galactose binding, soluble 1 3.31 2.0 3.53
411696 EST 3.29 1.4 3.53
AV019210 Eln 13717 elastin 3.29 1.8 3.53
AV084625 BTB (POZ) domain containing 1 3.29 1.6 3.53
AV037171 BC064011 407790 ESTs, Weakly similar to NUML mouse NADH-ubiquinone
oxidoreductase MLRQ subunit (M. musculus)
3.28 1.3 3.53
BG063257 2510027N19Rik 67711 RIKEN cDNA 2510027N19 gene 3.28 1.6 3.53
AV033994 Prg1 19073 proteoglycan, secretory granule 3.27 3.7 3.53
AV081086 EST 3.27 1.7 3.53
412241 EST 3.25 1.4 3.53
AV006019 Pigq 14755 phosphatidylinositol glycan, class Q 3.24 1.7 3.53
AV013830 S100a13 20196 S100 calcium binding protein A13 3.24 1.3 3.53
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AV015250 DnaJ (Hsp40) homolog, subfamily B, member 5 3.24 2.6 3.53
204387 EST 3.24 1.6 3.53
AW323058 Hsd17b4 15488 CD63 antigen 3.23 1.5 3.53
AI574416 Tgfb2 21808 transforming growth factor, beta 2 3.23 1.8 3.53
BG063870 Actb 11461 actin, beta, cytoplasmic 3.22 1.3 3.53
410751 EST 3.22 1.4 3.53
431101 EST 3.22 1.7 3.53
410791 EST 3.21 1.5 3.53
BE307724 Psap 19156 prosaposin 3.20 1.4 3.53
AV073780 Txln 109658 RIKEN cDNA 2600010N21 gene 3.19 1.9 3.53
AV308712 GLI-Kruppel family member GLI 3.19 1.4 3.53
BG072588 RIKEN cDNA 2410030A14 gene 3.19 1.4 3.53
AV074050 retinol binding protein 1, cellular 3.18 1.8 3.53
AV035206 Ehhadh 74147 RIKEN cDNA 1300002P22 gene 3.17 2.1 3.53
AV094410 5430413I02Rik 56742 differential display and activated by p53 3.17 1.3 3.53
AV171092 Actc1 11464 actin, alpha, cardiac 3.17 1.2 3.53
411087 EST 3.16 1.5 3.53
BG064536 Kdelr2 66913 RIKEN cDNA 1110007A14 gene 3.16 1.6 3.53
AA776162 CACNA1B 774 calcium channel, voltage-dependent, L type, alpha 1B subunit 3.15 1.6 3.73
AV162471 EST 3.15 2.1 3.73
AV041829 thymosin, beta 10 3.15 2.3 3.73
412704 EST 3.15 1.3 3.73
AV089281 Col5a2 12832 procollagen, type V, alpha 2 3.14 2.4 3.73
AV109643 Niemann Pick type C2 3.14 2.0 3.73
AI325874 Hspe1 15528 heat shock 10-kDa protein 1 (chaperonin 10) 3.13 1.5 3.73
432933 EST 3.13 1.3 3.73
BG065380 Pkm2 18746 pyruvate kinase 3 3.13 1.3 3.73
BG063305 Atp1b1 11931 ATPase, Na
þ/K
þ transporting, beta 1 polypeptide 3.12 1.3 3.73
BG069782 Hsd17b4 15488 CD63 antigen 3.10 1.5 3.73
BG064917 Tmem14c 66154 RIKEN cDNA 1110021D01 gene 3.10 1.3 3.73
BG072879 2610524G07Rik 66494 cytochrome P450, steroid inducible 3a11 3.10 1.3 3.73
AV093637 Pafah1b3 18476 platelet-activating factor acetylhydrolase, isoform 1b,
alpha 1 subunit
3.09 1.4 3.73
AV052389 Spink4 20731 serine protease inhibitor, Kazal type 4 3.09 2.6 3.73
RW:284 EST 3.08 3.7 3.73
AV094857 2410003B16Rik 72333 RIKEN cDNA 2410003B16 gene 3.08 1.4 3.73
411234 EST 3.08 1.9 3.73
AV156366 glyceraldehyde 3-phosphate dehydrogenase 3.08 1.6 3.73
41261 EST 3.08 1.8 3.73
BG066823 Ckmt1 12716 creatine kinase, mitochondrial 1, ubiquitous 3.07 1.5 3.73
AV028632 RIKEN cDNA 5530601H04 gene 3.07 1.9 3.73
AV094958 Sec22l1 20333 SEC22 vesicle trafficking protein-like 1 (S. cerevisiae) 3.07 1.4 3.73
X77585 Txn1 22166 thioredoxin 1 3.07 1.6 3.73
AV049504 EST, weakly similar to RL37 human 60S ribosomal
protein L37 (R. norvegicus)
3.07 1.2 3.73
412915 EST 3.06 1.6 3.73
BG071240 Cox7c 12867; 18738 phosphatidylinositol transfer protein 3.06 1.3 3.73
AV088363 Rplp2 67186 ribosomal protein, large P2 3.06 1.4 3.73
AW989643 EST 3.05 1.9 3.73
AV149918 Car2 12349 carbonic anhydrase 2 3.05 2.1 3.74
AV084873 Laptm5 16792 lysosomal-associated protein transmembrane 5 3.05 1.7 3.74
BG072998 Expressed sequence AU018638 3.04 1.8 3.74
413190 EST 3.03 1.3 3.74
AA000350 Fbn1 14118 fibrilin 1 3.02 1.6 3.74
BG075073 Tmsb4x 19241 thymosin, beta 4, X chromosome 3.02 1.7 3.74
AA693053 Ptpn2 19255 protein tyrosine phosphatase, non-receptor type 2 3.02 1.5 3.74
AV035959 Rps21 66481 RIKEN cDNA 2410030A14 gene 3.02 1.3 3.74
BG069532 Npc2 67963 Niemann Pick type C2 3.01 1.4 3.74
AV083728 Npc2 67963 Niemann Pick type C2 3.01 1.4 3.74
AA410137 EST 3.00 1.3 3.74
AV082005 0610040D20Rik 66070 RIKEN cDNA 0610040D20 gene 3.00 1.5 3.74
AV103733 Emp3 13732 epithelial membrane protein 3 3.00 1.4 3.74
BG063700 Sri 109552 RIKEN cDNA 2210417O06 gene 2.99 1.5 3.74
AA608500 S100a6 20200 S100 calcium binding protein A6 (calcyclin) 2.99 1.6 3.74
AI836995 432684 nascent polypeptide-associated complex alpha polypeptide 2.99 1.3 3.74
431042 EST 2.99 1.6 3.74
AV094984 Aldoa 11674 aldolase 1, A isoform 2.99 1.6 3.74
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e254 1126
Inflammatory Manifestations of LymphedemaTable 3. Continued
Gene ID Gene
Symbol
LocusLink
Accession ID
Gene Name Score
(d)
a
Fold
Change
q-Value
(%)
AV057697 Fbxo44 230903 Expressed sequence AV001623 2.98 1.3 3.74
AV110745 uncoupling protein 2, mitochondrial 2.98 1.5 3.74
AV025885 Cald1 109624; 18153 M. musculus, similar to caldesmon 1, clone MGC:30319
IMAGE:5148205, mRNA, complete cds
2.98 3.1 3.74
BG070959 Ralbp1 19765 Ral-interacting protein 1 2.98 1.4 3.74
AV166088 Zyx 22793 zyxin 2.96 1.6 3.74
AV061097 Selk 80795 heat shock 30-kDa protein 2.96 1.3 3.74
AV031183 cytochrome c oxidase, subunit Vb 2.96 1.4 3.74
AI325844 Prg1 19073 proteoglycan, secretory granule 2.96 2.6 3.74
BG076355 Stat3 20848 signal transducer and activator of transcription 3 2.95 1.3 3.74
AV140511 Cox7a2l 20463 cytochrome c oxidase subunit VIIa polypeptide 2-like 2.95 1.2 3.74
AV078179 selenoprotein W, muscle 1 2.95 1.7 3.74
AV086834 BCL2/adenovirus E1B 19-kDa interacting protein 1, NIP3 2.94 1.7 3.74
AW550270 Tnc 21923; 402769 tenascin C 2.93 5.2 3.74
AV109501 M. musculus, similar to spondin 1a, clone MGC:18859
IMAGE:4221758, mRNA, complete cds
2.93 1.7 3.74
AV103910 Rab11a 53869 RAB11a, member RAS oncogene family 2.93 1.4 3.74
411848 EST 2.93 1.6 3.74
AV094787 Mrpl1 94061 mitochondrial ribosomal protein L1 2.92 1.6 4.03
410746 EST 2.92 1.8 4.03
BG072740 Arpc3 56378 actin related protein 2/3 complex, subunit 3 (21 kDa) 2.92 1.6 4.03
AA261240 Sox18 20672 SRY-box containing gene 18 2.92 1.8 4.03
410959 EST 2.91 1.5 4.03
BG064603 Rshl2 66832 ribosomal protein L41 2.91 1.4 4.03
431066 EST 2.90 1.2 4.03
432500 EST 2.90 1.4 4.03
AV109648 Rbbp4 19646 retinoblastoma binding protein 4 2.90 2.0 4.03
BG073560 Cfl1 12631 cofilin 1, non-muscle 2.89 1.7 4.03
AV133972 Hnrpa1 15382 heterogeneous nuclear ribonucleoprotein A1 2.89 1.8 4.03
411828 EST 2.88 1.2 4.03
AV086965 calmodulin 1 2.88 1.5 4.03
AV095050 Hspa8 15481 heat shock 70-kDa protein 8 2.87 1.5 4.03
AV094992 procollagen, type IX, alpha 3 2.87 1.6 4.03
BG066918 Timm8b 30057 translocase of inner mitochondrial membrane 8 homolog
b (Saccharomyces cerevisiae)
2.87 1.5 4.03
AV108774 Prcp 72461 RIKEN cDNA 2510048K03 gene 2.86 2.4 4.03
BG074443 Lgals7 16858 lectin, galactose binding, soluble 7 2.86 1.3 4.03
AV104097 basigin 2.86 1.7 4.03
BG063004 Lgals1 16852 lectin, galactose binding, soluble 1 2.85 2.5 4.03
AV105178 ESTs 2.85 1.6 4.03
AV142972 EST 2.85 1.6 4.03
AV029181 Syt4 20983 synaptotagmin 4 2.84 2.8 4.03
BG072227 Litaf 56722 LPS-induced TNF-alpha factor 2.84 1.3 4.03
BG075934 Taldo1 21351 transaldolase 1 2.83 1.3 4.28
431681 EST 2.83 1.7 4.28
AV081042 serine protease inhibitor 8 2.83 1.3 4.28
BG063024 Efhd2 27984 RIKEN cDNA 2600015J22 gene 2.83 1.4 4.28
AV068926 hypoxia inducible factor 1, alpha subunit 2.83 1.4 4.28
BG064187 Rps18 20084 ribosomal protein S18 2.82 1.2 4.28
AV133978 Taf6l 225895 Similar to TAF6-like RNA polymerase II, p300/CBP-associated
factor (PCAF)-associated factor, 65 kD
2.82 1.8 4.28
AV089437 keratin complex 1, acidic, gene 13 2.81 2.2 4.28
410900 EST 2.81 2.9 4.28
AV073989 2310046G15Rik 76453; 69404 RIKEN cDNA 2310046G15 gene 2.81 1.7 4.28
BF720949 Nfkb1 18033 nuclear factor of kappa light chain gene enhancer
in B cells 1, p105
2.80 1.5 4.28
AV051965 Siat7d 20448 sialyltransferase 7 2.79 1.8 4.28
AV094533 Ctsl 13039 cathepsin L 2.79 1.3 4.28
AV130661 225307; 15382 heterogeneous nuclear ribonucleoprotein A1 2.79 1.7 4.28
AA080001 Calm1 12313 calmodulin 1 2.79 1.5 4.28
AV109477 Ctsl 13039 cathepsin L 2.79 1.5 4.28
AA066030 Hspa2 15512 heat shock 70-kDa protein 2 2.78 1.4 4.28
BG065539 RIKEN cDNA 3110023E09 gene 2.78 1.5 4.28
AV095469 ribosomal protein L19 2.78 1.3 4.28
BG071748 Ube2s 77891 RIKEN cDNA 6720465F12 gene 2.78 1.8 4.28
411794 EST 2.78 1.5 4.28
BG070325 Nsep1 22608 nuclease sensitive element binding protein 1 2.78 1.3 4.28
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are distorted [2]. Architectural changes in the skin and
subcutaneous tissues are often profound [3]. Chronic lymph
stasis typically stimulates an increase in the number of
ﬁbroblasts, adipocytes, and keratinocytes in the skin. Mono-
nuclear cells (chieﬂy macrophages) often demarcate the
chronic inﬂammatory response [3]. In affected tissues, there
is an increase in collagen deposition, accompanied by adipose
and connective tissue overgrowth in the edematous regions
[26].
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AV070988 Mtch2 56428 mitochondrial carrier homolog 2 2.77 1.2 4.28
BG064794 Ftl1 14325 ferritin light chain 1 2.77 2.3 4.28
AI596209 Ror2 26564; 78531 receptor tyrosine kinase-like orphan receptor 2 2.77 1.4 4.28
AA815993 Acta2 11475 actin, alpha 2, smooth muscle, aorta 2.77 1.7 4.28
AV039554 Dmrtb1 56296 proline-rich protein 13 2.76 1.5 4.28
AV094728 eukaryotic translation initiation factor 4E 2.76 1.3 4.28
BG064454 Tax1bp3 76281 RIKEN cDNA 1300011C24 gene 2.76 1.4 4.28
AV006514 Ifnar2 15976 interferon (alpha and beta) receptor 2 2.76 1.5 4.28
AV086929 RIKEN cDNA 9430096L06 gene 2.75 1.8 4.28
BG063866 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)
ubiquitously expressed (fox-derived)
2.75 1.3 4.28
BG072299 2210401K01Rik 72289 receptor (calcitonin) activity modifying protein 2 2.75 1.4 4.28
412038 EST 2.75 1.4 4.28
BG067962 1110020C13Rik 66151 RIKEN cDNA 1110020C13 gene 2.75 1.4 4.28
412958 EST 2.75 1.4 4.28
AI226124 Itgb1 16412 integrin beta 1 (fibronectin receptor beta) 2.74 1.6 4.90
BG066897 Ubl5 66177 ubiquitin-like 5 2.74 1.2 4.90
AV067886 RIKEN cDNA 1810027O10 gene 2.74 1.5 4.90
AV086649 Gmnn 57441 geminin 2.73 1.7 4.90
AV023199 selenoprotein W, muscle 1 2.73 2.2 4.90
AV095185 Rps21 66481 RIKEN cDNA 2410030A14 gene 2.73 1.2 4.90
AV033362 1500040F11Rik 22272 RIKEN cDNA 1500040F11 gene 2.73 1.3 4.90
AW557788 Flna 192176 filamin-like protein 2.72 1.5 4.90
BG070952 Vkorc1l1 69568 RIKEN cDNA 2310024K08 gene 2.72 1.3 4.90
AV084361 RIKEN cDNA 1810036J22 gene 2.72 1.6 4.90
BG063730 A4galt 239559 ESTs 2.71 1.3 4.90
AV086045 Cox7c 12867; 18738 phosphatidylinositol transfer protein 2.71 1.5 4.90
BG063539 Rps20 67427 ribosomal protein S20 2.71 1.2 4.90
BG072985 Rpl7 19989 ribosomal protein L7 2.71 1.3 4.90
AV093845 Atp5e 67126 RIKEN cDNA 2410043G19 gene 2.71 1.6 4.90
BG068855 Rhoa 11848 ribosomal protein L13a 2.70 1.3 4.90
AV094701 Pnkp 59047 polynucleotide kinase 39-phosphatase 2.69 1.3 4.90
BG072570 Rplp2 67186 ribosomal protein, large P2 2.69 1.3 4.90
AV123125 Lgals1 16852 lectin, galactose binding, soluble 1 2.69 2.9 4.90
BG072625 ribosomal protein L19 2.68 1.4 4.90
AV058085 EST 2.68 1.2 4.90
AV008001 ESTs 2.68 1.5 4.90
AA796822 Siat4a 20442 sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) 2.68 1.8 4.90
W71612 Rab11b 19326 RAB11b, member RAS oncogene family 2.68 1.5 4.90
BG063081 Tmsb10 19240 thymosin, beta 10 2.67 2.2 4.90
AV015233 ESTs 2.67 2.8 4.90
AV061059 Lyn 17096; 70720 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 2.67 2.1 4.90
AV094452 Dnclc1 56455 dynein, cytoplasmic, light chain 1 2.66 1.5 4.90
AV171729 EST 2.66 1.3 4.90
AV094762 0610042I15Rik 56418 prenylated SNARE protein 2.66 1.2 4.90
AV111434 Myl9 98932 transient receptor protein 2 2.65 1.5 4.90
AV020423 2900073G15Rik 67268 RIKEN cDNA 2900073G15 gene 2.65 1.4 4.90
BG064580 ESTs 2.65 1.3 4.90
AV033259 Hrmt1l2 15469 heterogeneous nuclear ribonucleoprotein
methyltransferase-like 2 (S. cerevisiae)
2.65 1.5 4.90
AV171094 Tcf4 21413 transcription factor 4 2.65 1.4 4.90
412427 EST 2.64 1.7 4.90
AV149856 Pfn1 18643 profilin 1 2.64 1.5 4.90
AV149997 5730405M13Rik 66627 RIKEN cDNA 5730405M13 gene 2.63 1.4 4.90
AV013452 Expressed sequence AW743884 2.63 2.4 4.90
AV071157 ESTs 2.63 1.3 4.90
AV065302 membrane-associated protein 17 2.63 1.3 4.90
aThe unit d is the relative difference in gene expression, as defined in [53].
DOI: 10.1371/journal.pmed.0030254.t003
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BG067123 Cdh1 12550 cadherin 1  14.33 2.27 0.91
BG074458 Dhcr24 74754 RIKEN cDNA 2310076D10 gene  11.37 2.17 0.91
AV008967 ferrochelatase  10.96 1.62 0.91
AV068725 Hod 74318; 330108 RIKEN cDNA 1200015P04 gene  9.82 1.44 0.91
AV030680 D7Ertd743e 233724 RIKEN cDNA 150031M19 gene  9.42 1.53 0.91
AI841373 Lxn 17035 latexin  8.82 1.97 0.91
BG066932 Grcc3f 14792 M. musculus, clone MGC:11670 IMAGE:3709076, mRNA, complete cds  7.61 1.60 0.91
411579 EST  7.55 1.89 0.91
AV087499 EST, moderately similar to A57474 extracellular matrix protein 1
precursor (M. musculus)
 7.48 1.41 0.91
AA607208 Cdh1 12550 cadherin 1  7.45 1.59 0.91
AV133742 EST  7.26 1.58 0.91
410895 EST  7.20 1.75 0.91
AV024056 Hal 15109 histindine ammonia lyase  7.20 1.39 0.91
410562 EST  6.90 1.77 0.91
BG069499 RIKEN cDNA 6330408J20 gene  6.75 1.31 0.91
AV017203 ESTs, highly similar to afadin (R. norvegicus)  6.64 1.66 0.91
BG066839 C80587 229504 Expressed sequence C80587  6.49 1.93 0.91
413288 EST  6.35 2.02 0.91
AV080417 Gsta4 14860 glutathione S-transferase, alpha 4  6.20 1.73 0.91
AV015934 Ccnd1 382098 cyclin D1  6.15 1.51 0.91
AV135760 434233 RIKEN cDNA 2600017P15 gene  6.08 1.37 0.91
AU040403 Krt1–5 16673 Expressed sequence AU040403  6.07 1.43 0.91
BG069581 Rhou 69581 ras homolog gene family, member U (M. musculus)  6.07 1.49 0.91
BG073053 D10Ertd214e 52637 protein tyrosine phosphatase, receptor type, f polypeptide  5.77 1.42 1.08
AI841275 3110006P09Rik 68036 RIKEN cDNA 2810030L11 gene  5.67 1.78 1.08
412117 EST  5.67 1.37 1.08
AV088691 Nrd1 230598 M. musculus, similar to N-arginine dibasic convertase 1  5.63 1.43 1.08
BG076206 Gng3lg 14705 G protein gamma 3 linked gene  5.61 1.29 1.08
AV074612 Cd164 53599 CD164 antigen  5.53 1.46 1.08
BG072568 Dusp14 56405 dual specificity phosphatase 14  5.52 1.43 1.08
AV081291 68539 RIKEN cDNA 1110006I15 gene  5.46 1.59 1.08
BG075873 67231 RIKEN cDNA 2810442O16 gene  5.44 1.86 1.08
AA111722 Ccnd1 12443 cyclin D1  5.42 1.54 1.08
AW552727 353049 fatty acid synthase  5.36 1.71 1.08
BG072524 Dgat2 67800 diacylglycerol O-acyltransferase 2  5.35 1.87 1.08
412975 EST  5.25 1.42 1.36
AV081155 Expressed sequence AV228068  5.23 1.74 1.36
BG071790 Ppp1cc 19047 protein phosphatase 1, catalytic subunit, gamma isoform  5.21 1.87 1.36
AA725946 keratin complex 1, acidic, gene 5  5.15 1.87 1.36
AV087069 Arhu 69581 ras homolog gene family, member U  5.09 1.75 1.36
AV085989 52637 Expressed sequence AU043390  5.06 1.69 1.36
BG071047 68036 RIKEN cDNA 3110006P09 gene  5.03 1.29 1.36
AV006223 Gsn 66623 gelsolin  5.03 1.81 1.36
AV106079 Gpsn2 106529 Expressed sequence AI173355  5.03 1.65 1.36
AV094491 108673 RIKEN cDNA 4933411H20 gene  4.92 1.46 1.36
AV057616 Atp6v1d 73834 ATPase, H
þ transporting, lysosomal 34 kDa, V1 subunit D  4.92 1.46 1.36
AV084670 Vil2 22350 villin 2  4.91 1.65 1.36
BG071281 Lap3 66988 leucine aminopeptidase 3  4.89 1.36 1.36
AV022852 73731 RIKEN cDNA 1110001M24 gene  4.88 1.70 1.36
AV005044 Gltp 56356 glycolipid transfer protein  4.88 1.47 1.36
AW554387 Sgpl1 20397 sphingosine phosphate lyase 1  4.88 2.03 1.36
BG069739 Hmgcs1 208715 pre–B cell leukemia transcription factor 1  4.87 1.53 1.36
BG064974 Hsd17b12 56348 hydroxysteroid (17-beta) dehydrogenase 12  4.85 1.50 1.36
AV086231 Sprrl9 67718 small proline rich-like 9  4.83 1.75 1.59
411558 EST  4.80 1.22 1.59
AV032378 109305 M. musculus, similar to hypothetical protein FLJ14466  4.75 1.52 1.59
AV012833 105072 Expressed sequence AA407887  4.74 1.14 1.59
AV029122 Gpr56 14766 G protein-coupled receptor 56  4.73 1.51 1.59
BG071157 Pcyt1a 13026 phosphate cytidylyltransferase 1, choline, alpha isoform  4.68 1.43 1.73
AV088664 Cdh1 12550 cadherin 1  4.65 1.77 1.73
BG074432 Egfl5 230316 ESTs, weakly similar to LMA1 laminin alpha-1 chain precursor (M. musculus)  4.65 1.64 1.73
AV074709 Srebf1 20787 sterol regulatory element binding factor 1  4.63 1.86 1.73
AV043450 Erbb2ip 59079 Erbb2 interacting protein  4.62 1.64 1.73
AV036580 Gsn 227753 gelsolin  4.57 1.72 1.73
BG066848 Expressed sequence AI429612  4.54 1.57 1.73
AV068741 Acly 104112 Expressed sequence AW538652  4.49 1.57 1.96
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BG070160 Rbm16 106583; 319358 Expressed sequence AI447644  4.48 1.35 1.96
413523 EST  4.46 1.62 1.96
BG072270 Tom1l2 216810 Expressed sequence AU042072  4.44 1.61 1.96
BG075104 Ecm1 13601 extracellular matrix protein 1  4.43 1.53 1.96
BG076113 1110002B05Rik 104725 RIKEN cDNA 3110040D16 gene  4.39 1.32 1.96
AV087190 Gsn 227753 gelsolin  4.38 1.52 1.96
AV134202 Mocs2 17434 molybdenum cofactor synthesis 2  4.35 1.56 2.28
BG076410 ESTs  4.34 1.51 2.28
411478 EST  4.32 1.44 2.28
412058 EST  4.31 1.34 2.28
AV143646 Rbbp6 19647 retinoblastoma binding protein 6  4.28 1.61
BG069784 Tcte1l 67117 RIKEN cDNA 2310075M16 gene  4.26 1.41 2.73
BG062974 104725 RIKEN cDNA 1110002B05 gene  4.25 1.75 2.73
BG075415 78334 Expressed sequence AW228747  4.25 1.44 2.73
BG064062 Klf4 16600 Kruppel-like factor 4 (gut)  4.23 1.83 2.73
BG075520 70174 Expressed sequence AW547365  4.18 1.26 2.73
AV020091 M. musculus, similar to hypothetical protein FLJ20552  4.17 1.56 2.73
BG075034 Hdac3 15183 histone deacetylase 3  4.15 1.39 2.73
AV057405 Mthfd2 17768 methylenetetrahydrofolate dehydrogenase (NAD
þ dependent),
methenyltetrahydrofolate cyclohydrolase
 4.15 1.62 2.73
BG071256 70564 RIKEN cDNA 5730469M10 gene  4.12 1.39 2.73
AV053048 Sel1h 20338 Expressed sequence AW493766  4.10 1.49 2.73
BG063086 104725 RIKEN cDNA 1110002B05 gene  4.10 1.53 2.73
AV086552 Ube2g2 22213 ubiquitin-conjugating enzyme E2G 2  4.04 1.52 3.17
AV140482 230584 M. musculus, similar to hypothetical protein, clone MGC:6903 IMAGE:2655774  4.03 1.32 3.17
AV085956 Mgea5 76055 RIKEN cDNA 2310016E22 gene  4.00 1.46 3.17
BG063211 Expressed sequence AA408215  3.99 1.46 3.17
AV059238 ESTs  3.98 1.50 3.17
AV089020 2410001H17Rik 66990 RIKEN cDNA 2410001H17 gene  3.95 1.42 3.17
AW551596 76783 ESTs, moderately similar to KIAA0874 protein (H. sapiens)  3.95 1.44 3.17
BG063986 Chc1 100088 RIKEN cDNA 4931417M11 gene  3.94 1.36 3.17
AU016967 Slc31a1 20529 RIKEN cDNA 4930445G01 gene  3.94 1.43 3.17
AV057445 Hist2h3c1 15077 histone gene complex 2  3.94 1.92 3.17
BG064592 Dph2l2 67728 RIKEN cDNA 9130020C19 gene  3.93 1.64 3.17
AV086468 2810442O16Rik 67231 RIKEN cDNA 2810442O16 gene  3.90 1.65 3.24
AV012729 Srebf1 67231 sterol regulatory element binding factor 1  3.90 1.60 3.24
AV021055 8-Sep 20787 septin 8  3.89 1.48 3.24
BG074257 Atp6v1h 108664 Expressed sequence AU022349  3.89 1.28 3.24
BG063838 353049 fatty acid synthase  3.88 1.79 3.24
AV012338 1110058A 66195 RIKEN cDNA 1110058A15 gene  3.85 1.80 3.24
AV033310 Ss18 synovial sarcoma translocation, Chromosome 18  3.82 1.34 3.24
AV012385 Sprrl10 small proline rich-like 10  3.80 1.82 3.24
AV005017 Sult4a1 29859 sulfotransferase family 4A, member 1  3.80 1.42 3.24
AV084927 Sh3glb2 227700 M. musculus SH3GLB2 mRNA, complete cds  3.79 1.45 3.24
AV133665 Dnajb1 81489 DnaJ (Hsp40) homolog, subfamily B, member 1  3.79 1.63 3.24
BG063266 Gclc 14629 glutamate-cysteine ligase, catalytic subunit  3.78 1.27 3.24
BG075637 Nf2 18016 neurofibromatosis 2  3.78 1.25 3.24
BG063956 Etf1 225363 M. musculus, eukaryotic translation termination factor 1,
clone MGC:18745 IMAGE:3992883
 3.78 1.31 3.24
BG072153 Mod1 17436 malic enzyme, supernatant  3.77 1.72 3.24
AV084064 Atp9a 11981; 436431 ATPase, class II, type 9A  3.76 1.64 3.53
BG065176 9130404D14Rik 227737 M. musculus, clone IMAGE:4038329, mRNA, partial cds  3.73 1.59 3.53
BG074922 Rnf167 70510 ring finger protein 167  3.71 1.29 3.53
BG075099 Rbbp6 19647 retinoblastoma binding protein 6  3.68 1.55 3.53
BG075709 Nt5c3 107569 RIKEN cDNA 2610206B05 gene  3.67 1.49 3.53
BG072411 Epb4.1l4b 54357 erythrocyte protein band 4.1-like 4b  3.66 1.51 3.53
AV085951 Calm4 80796 calmodulin 4  3.65 1.30 3.53
AV041686 Rmp 19777 RPB5-mediating protein  3.64 1.79 3.53
BG063540 Sypl 19027 pantophysin  3.63 1.32 3.73
BG063290 Nfe2l1 18023 nuclear factor, erythroid-derived 2-like 1  3.62 1.38 3.73
AF249870 Perp 64058 p53 apoptosis effector related to Pmp22  3.62 1.30 3.73
AV013952 1300007F 67477 RIKEN cDNA 1300007F04 gene  3.62 1.53 3.73
AV065655 Hod 74318; 330108 RIKEN cDNA 1200015P04 gene  3.60 1.61 3.73
BG074645 2210413I1 109004 ESTs, moderately similar to T42707 hypothetical protein
DKFZp586EO41.1 (H. sapiens)
 3.59 1.44 3.73
BG063778 Dag1 13138 dystroglycan 1  3.58 1.30 3.73
AV015196 Expressed sequence AI195353  3.58 1.81 3.73
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BG068048 1110007A06Rik 68477 Hypothetical protein, clone MTA.D02.090  3.57 1.38 3.73
AV034519 Hmgcr 15357 3-hydroxy-3-methylglutaryl-coenzyme A reductase  3.54 1.48 3.73
AU020667 Uchl3 50933 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase)  3.54 1.31 3.73
AV094982 Rgs19ip1 67903 regulator of G-protein signaling 19 interacting protein 1  3.54 1.50 3.73
AA106674 Ltbp4 108075 RIKEN cDNA 2310046A13 gene  3.53 1.50 3.73
BG070746 1110067D22Rik 216551 RIKEN cDNA 1110067D22 gene  3.51 1.48 3.74
BG064041 0610011N22Rik 67433 RIKEN cDNA 0610011N22 gene  3.49 1.34 3.74
AV049386 0610039C 66853 RIKEN cDNA 0610039C21 gene  3.49 1.44 3.74
AI840878 Hod 74318; 330108 RIKEN cDNA 1200015P04 gene  3.49 1.54 3.74
AV105934 Sphk1 20698 sphingosine kinase 1  3.47 1.68 3.74
AV085893 D10Ertd21 52637 Expressed sequence AU043990  3.47 1.62 3.74
AA118482 Edg4 53978 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor 4  3.45 1.25 3.74
BG063967 9130207N01 212684 M. musculus, clone MGC:7094 IMAGE:3157493, mRNA, complete cds  3.44 1.48 3.74
AV031353 M. musculus, similar to phosphatidylserine decarboxylase, clone
MGC:7133 IMAGE:3158145,
 3.44 1.70 3.74
AV162240 Irf3 54131 interferon regulatory factor 3  3.43 1.24 4.03
AV162274 3110001I2 70354 RIKEN cDNA 3110001I20 gene  3.42 1.92 4.03
BG072974 Neo1 18007 ESTs  3.40 1.53 4.03
AV005287 Scamp2 24044 secretory carrier membrane protein 2  3.37 1.19 4.03
AV089034 Expressed sequence AI316859  3.37 1.41 4.03
BG069319 Baz2a 116848 Expressed sequence AA415431  3.37 1.61 4.03
AV087585 Noc4 18117 neighbor of Cox4  3.36 1.35 4.03
AA863549 Notch1 18128 Notch gene homolog 1 (Drosophila)  3.36 2.07 4.03
BG075813 Hipk1 15257 homeodomain interacting protein kinase 1  3.36 1.38 4.03
BG075318 3100002M 69276 RIKEN cDNA 4933429H19 gene  3.35 1.29 4.03
AV024434 1200003E16Rik 66860 RIKEN cDNA 1200003E16 gene  3.35 1.66 4.03
BG074608 1110003H 68561 RIKEN cDNA 1300009F09 gene  3.34 1.41 4.03
AV084667 Tuft1 22156 tuftelin 1  3.33 1.56 4.03
AV087829 Clic3 69454 chloride intracellular channel 3  3.33 1.72 4.03
BG063343 Dhcr7 13360 7-dehydrocholesterol reductase  3.33 1.65 4.03
AV052668 1810018L0 70380 RIKEN cDNA 1810018L05 gene  3.32 1.51 4.03
AI194827 Osbpl1a 64291 oxysterol binding protein-like 1A  3.31 1.80 4.03
410847 EST  3.31 1.41 4.28
AV093444 Golga7 57437; 71655 hypothetical protein, MNCb-1213  3.29 1.25 4.28
BG076201 Vil2 22350 villin 2  3.29 1.29 4.28
AV021431 Mkrn1 54484 ESTs  3.29 1.39 4.28
BG072487 3110018K 73122 RIKEN cDNA 3110118K12 gene  3.27 1.37 4.28
AV084649 Ldb1 16825 LIM domain binding 1  3.27 1.36 4.28
AV081983 Hop 74318 RIKEN cDNA 1200015P04 gene  3.27 1.51 4.28
AV055811 Ugalt2 110172 UDP-galactose translocator 2  3.26 1.22 4.28
BG075832 Ccnd2 12444 cyclin D2  3.26 1.50 4.28
413170 EST  3.24 1.38 4.28
BG070048 Hipk1 15257 homeodomain interacting protein kinase 1  3.24 1.30 4.28
AV040013 Tes3 114893 Expressed sequence C85469  3.23 1.36 4.28
AV084288 Sprrl2 73722 small proline rich-like 2  3.22 1.60 4.90
AV093474 1300009F 66890 RIKEN cDNA 1300009F09 gene  3.19 1.35 4.90
AV149993 Rnf167 70510 ring finger protein 167  3.19 1.49 4.90
411517 EST  3.18 1.36 4.90
BG075876 Atp9a 11981; 436431 ATPase, class II, type 9A  3.18 1.31 4.90
BG075368 LOC21616 216169 M. musculus, similar to CGI-67 protein, clone MGC:11699
IMAGE:3964094, mRNA, complete cds
 3.17 1.48 4.90
410554 EST  3.17 1.43 4.90
BG071335 5730469M 70564 RIKEN cDNA 5730469M10 gene  3.16 1.54 4.90
BG074934 2810037C 67211 RIKEN cDNA 2810037C14 gene  3.16 1.42 4.90
BG063413 CD2 antigen (cytoplasmic tail) binding protein 2  3.14 1.32 4.90
aThe unit d is the relative difference in gene expression, as defined in [53].
DOI: 10.1371/journal.pmed.0030254.t004
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e254 1131
Inflammatory Manifestations of LymphedemaTable 5. Pathway Analysis for Upregulated Genes in Lymphedema versus Normal Control (SAM, FDR , 0.05)
System Gene Category List
Hits
List
Total
Population
Hits
Population
Total
p-Value Unigene Clusters
GO Biological
Process
Response to pest/pathogen/parasite 11 101 252 10,778 0.0001 MM.163; MM.2128; MM.22673; MM.23905;
MM.249934; MM.2570; MM.3453; MM.45436;
MM.465; MM.653; MM.8655
Immune response 14 101 451 10,778 0.0003 MM.141021; MM.163; MM.1776; MM.2128;
MM.22673; MM.23905; MM.249934;
MM.2570; MM.3453; MM.45436; MM.465;
MM.549; MM.653; MM.8655
Response to stress 15 101 538 10,778 0.0004 MM.1090; MM.12145; MM.163; MM.203;
MM.2128; MM.22673; MM.23905; MM.249934;
MM.2570; MM.29057; MM.3453; MM.45436;
MM.465; MM.653; MM.8655
Response to biotic stimulus 16 101 606 10,778 0.0004 MM.1090; MM.141021; MM.163; MM.1776;
MM.2128; MM.22673; MM.23905; MM.249934;
MM.2570; MM.29865; MM.3453; MM.45436;
MM.465; MM.549; MM.653; MM.8655
Defense response 15 101 553 10,778 0.0006 MM.141021; MM.163; MM.1776; MM.2128;
MM.22673; MM.23905; MM.249934;
MM.2570; MM.29865; MM.3453; MM.45436;
MM.465; MM.549; MM.653; MM.8655
Complement activation 4 101 36 10,778 0.0044 MM.2570; MM.3453; MM.653; MM.8655
Humoral immune response 5 101 76 10,778 0.0054 MM.2570; MM.3453; MM.45436; MM.653; MM.8655
Humoral defense mechanism (sensu Vertebrata) 4 101 42 10,778 0.0068 MM.2570; MM.3453; MM.653; MM.8655
Nicotinamide metabolism 3 101 14 10,778 0.0072 MM.21454; MM.29182; MM.4222
Pyridine nucleotide metabolism 3 101 15 10,778 0.0083 MM.21454; MM.29182; MM.4222
Oxidoreduction coenzyme metabolism 3 101 17 10,778 0.0106 MM.21454; MM.29182; MM.4222
Carbohydrate metabolism 8 101 304 10,778 0.0228 MM.14825; MM.180337; MM.21743;
MM.2284; MM.29182; MM.29357;
MM.4222; MM.45436
Water-soluble vitamin metabolism 3 101 30 10,778 0.0313 MM.21454; MM.29182; MM.4222
Response to external stimulus 17 101 1,070 10,778 0.0370 MM.1090; MM.141021; MM.163; MM.1776;
MM.196464; MM.2128; MM.22673; MM.23905;
MM.249934; MM.2570; MM.29865; MM.3453;
MM.45436; MM.465; MM.549; MM.653; MM.8655
Main pathways of carbohydrate metabolism 4 101 80 10,778 0.0381 MM.14825; MM.21743; MM.29182; MM.4222
GO Cellular
Component
Extracellular space 42 112 2,198 10,767 0.0000 MM.10299; MM.10406; MM.141312; MM.163;
MM.17185; MM.172; MM.181021; MM.182434;
MM.18625; MM.19844; MM.2128; MM.21767;
MM.22194; MM.22673; MM.22699; MM.2277;
MM.23905; MM.2412; MM.2570; MM.2608;
MM.27343; MM.28231; MM.28484; MM.29599;
MM.29778; MM.3014; MM.3453; MM.36661;
MM.41560; MM.43831; MM.45436; MM.46053;
MM.465; MM.549; MM.653; MM.7091; MM.7281;
MM.738; MM.8655; MM.86922; MM.9537; MM.980
Collagen 5 112 34 10,767 0.0004 MM.10299; MM.141312; MM.181021; MM.7281;
MM.738
Mitochondrion 17 112 618 10,767 0.0006 MM.10406; MM.1090; MM.14825; MM.18625;
MM.20801; MM.21454; MM.215667; MM.2159;
MM.21743; MM.24108; MM.251621; MM.29057;
MM.29599; MM.30072; MM.3014; MM.400; MM.8688
Cytoplasm 55 112 3,659 10,767 0.0009 MM.10406; MM.1090; MM.121878; MM.141741;
MM.142095; MM.142729; MM.14825; MM.153911;
MM.17185; MM.181880; MM.18625; MM.196484;
MM.20801; MM.21454; MM.215667; MM.2159;
MM.21743; MM.2241; MM.2277; MM.2284;
MM.24108; MM.2412; MM.24608; MM.249934;
MM.251621; MM.2551; MM.260084; MM.2734;
MM.28100; MM.28622; MM.28693; MM.29057;
MM.29182; MM.29357; MM.29599; MM.29997;
MM.30072; MM.3014; MM.34246; MM.3532;
MM.3746; MM.38055; MM.400; MM.4024;
MM.41560; MM.4222; MM.42790; MM.6523;
MM.686; MM.7091; MM.741; MM.757; MM.831;
MM.83909; MM.8688
Mitochondrial matrix 4 112 64 10,767 0.0282 MM.14825; MM.21743; MM.24108; MM.29599
Collagen type V 2 112 3 10,767 0.0306 MM.10299; MM.7281
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Inflammatory Manifestations of LymphedemaIn the current study, the molecular expression proﬁle of
lymphedema, observed in parallel with the histopathology
and the dynamic immune trafﬁc imaging, suggests that the
deranged immune trafﬁc plays at least a passive, if not an
active, role in the pathogenesis of the disorder. In normal
immune trafﬁc, mononuclear phagocytes and lymphocytes
from the tissues enter the afferent lymph vessels and the
lymph nodes to elicit primary immune responses before
reentering the vasculature [5]. It is conceivable that, in
chronic lymphedema, the impairment of lymphocyte and
Langerhans cell trafﬁcking from skin to regional lymph nodes
leads to inefﬁcient clearance of foreign antigens, and
provides the substrate for chronic inﬂammatory changes [4].
The complex biology of lymphedema is still quite poorly
understood. Although it has been conjectured that inﬂam-
mation may indeed trigger various forms of lymphangio-
genesis [27,28], the physiological sensors, signaling
mechanisms, and cause-and-effect relationships that initiate
post-natal lymphangiogenesis remain to be elucidated.
Transcriptional proﬁling has been utilized to identify genes
activated in disease states and to reﬁne targets for molecular
therapy. Microarray technology has been applied to the
elucidation of endothelial biology in health and disease [9,29],
as well as to the investigation of gene expression patterns in
cutaneous diseases [30] and in a wide array of non-neoplastic
diseases that entail inﬂammatory or immune responses [31].
This approach is particularly attractive for the problem of
acquired lymphedema, where the heterogeneous cellular
composition of the tissues exposed to lymph stagnation
presupposes a very complex, interdependent pattern of gene
expression. While the characteristic expression proﬁles of
isolated lymphatic endothelia have previously been studied
[6,7], the current investigation represents the ﬁrst in-depth
molecular examination of the end-organ response to lymph
stagnation. Despite the heterogeneous nature of the cellular
material under investigation, the approach of high-through-
put transcriptional proﬁling and statistical gene ontology
analysis has disclosed discernable patterns of gene expression
that appear to be representative of the disorder under
scrutiny.
Transcriptional proﬁling can provide not only a gene-by-
gene view of physiological alterations in a diseased state, but
also a statistically rigorous identiﬁcation of the biological
processes that are induced or repressed in disease. This
provides a much broader and more comprehensive view of
the disease process as a whole than does a simple gene list,
making generation of hypotheses about mechanisms more
informed. Based on GO functional annotations for each gene
on the array [32], we used Fisher’s exact test statistical analysis
to identify functional processes that are signiﬁcantly induced
and repressed in this disease model (Table 7). The results of
this analysis were quite interesting, illustrating that whole
panels of genes involved in the immune response, stress
response, and complement activation are induced in lym-
phedema when compared to controls. Among the most
interesting of the upregulated genes involved in these
processes are many encoding proteins that reﬂect the
inﬂammatory process. Calgranulin B, highly upregulated in
this experimental model, belongs to a family of small calcium-
binding proteins that are highly expressed in neutrophil and
monocyte cytosol. These molecules are found at high levels in
the extracellular milieu during inﬂammatory conditions [33].
Table 5. Continued
System Gene Category List
Hits
List
Total
Population
Hits
Population
Total
p-Value Unigene Clusters
Mitochondrial membrane 6 112 174 10,767 0.0339 MM.10406; MM.18625; MM.251621; MM.29057;
MM.3014; MM.400
Mitochondrial electron transport chain 3 112 32 10,767 0.0427 MM.251621; MM.3014; MM.400
GO Molecular
Function
Defense/immunity protein activity 9 109 129 11,303 0.0000 MM.141741; MM.1776; MM.2570; MM.28231;
MM.3453; MM.45436; MM.465; MM.653; MM.8655
Extracellular matrix structural 6 109 68 11,303 0.0005 MM.10299; MM.141312; MM.181021; MM.29865;
MM.7281; MM.738
Complement activity 4 109 24 11,303 0.0015 MM.2570; MM.3453; MM.653; MM.8655
Structural molecule activity 14 109 591 11,303 0.0041 MM.10299; MM.107869; MM.121878; MM.141312;
MM.181021; MM.24108; MM.29057; MM.29599;
MM.29865; MM.29982; MM.42790; MM.686;
MM.7281; MM.738
Actin binding 7 109 179 11,303 0.0073 MM.121878; MM.141741; MM.142729; MM.153911;
MM.30059; MM.3532; MM.4024
Heparin binding 4 109 47 11,303 0.0101 MM.182434; MM.23905; MM.46053; MM.7281
Isomerase activity 5 109 100 11,303 0.0153 MM.2412; MM.28100; MM.28622; MM.29357; MM.4222
Antimicrobial peptide activity 3 109 22 11,303 0.0184 MM.141741; MM.28231; MM.45436
Glycosaminoglycan binding 4 109 59 11,303 0.0187 MM.182434; MM.23905; MM.46053; MM.7281
Structural constituent of muscle 3 109 28 11,303 0.0291 MM.121878; MM.29057; MM.686
Electron transporter activity 6 109 181 11,303 0.0296 MM.10406; MM.21062; MM.28622; MM.30072;
MM.38746; MM8688
Cytoskeletal protein binding 7 109 248 11,303 0.0315 MM.121878; MM.141741; MM.142729; MM.153911;
MM.30059; MM.3532; MM.4024
Hydrolase activity, acting on glycosyl bonds 4 109 82 11,303 0.0436 MM.180337; MM.203; MM.2284; MM.45436
Oxidoreductase activity, acting on the CH-OH
group of donors, NAD, or NADP as acceptor
4 109 86 11,303 0.0491 MM.14825; MM.21454; MM.21743; MM.28100
DOI: 10.1371/journal.pmed.0030254.t005
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Inflammatory Manifestations of LymphedemaCalgranulins are potent stimulators of neutrophils and likely
are involved in neutrophil migration to inﬂammatory sites.
The levels of several of these proteins are markedly elevated
in psoriasis, among other conditions [34]. Tenascin C is
strongly induced by various pro- and anti-inﬂammatory
cytokines, and its de novo expression is a reliable molecular
marker for acute inﬂammation [35]. Peptidylprolyl isomerase
B, also known as cyclophilin B, induces chemotaxis and
integrin-mediated adhesion of T cells to the extracellular
matrix in vitro [36]. Basigin is also involved in inﬂammatory
processes and is proposed to be a receptor of cyclophilin A.
Stromal cell-derived factor 1, also known as CXCL12, is a
highly efﬁcacious lymphocyte chemoattractant [37]. Platelet
factor 4, also known as CXCL4, is a strong chemoattractant
for neutrophils and ﬁbroblasts. In addition to its putative role
in inﬂammation, it has been implicated in the pathogenesis of
atopic dermatitis. Upregulation of arachidonate 5-lipoxyge-
nase activating protein suggests a role for leukotrienes in this
acute inﬂammatory response; glutathione peroxidase may
play an ancillary role. CD63 antigen can be interpreted as a
marker of basophil activation and of degranulated neutro-
phils and monocytes. Legumain, an asparaginyl endopepti-
dase central to Class II major histocompatiblity complex
presentation of microbial antigens, is a potential molecular
marker of macrophage differentiation and function [38].
Follistatin is an activin antagonist implicated in wound
repair; activin is an important participant in inﬂammation,
repair, and cytoprotection in various organs, but its
induction is restricted to certain types of inﬂammation and
its release is dependent upon the inﬂammatory setting [39].
Nuclear factor kappa B is a transcription factor critical to the
expression of a variety of chronic inﬂammatory disease states.
The downregulation of gelsolin in this model is notable,
inasmuch as hemostatic, inﬂammatory, and ﬁbroblast re-
sponses are blunted in mice lacking gelsolin. Expression of
nascent polypeptide-associated complex regulates formation
of Fas-associated death domain (FADD) protein oligomers
and modulates FADD-mediated signaling; FADD protein is a
critical mediator of signal transduction pathways activated by
several members of the tumor necrosis factor (TNF) receptor
gene superfamily. Cathepsins are distinct intracellular acidic
proteases that actively participate in the mechanism of
antigen processing; conversely, the steﬁns are inhibitors of
these cathepsins.
The immune response process is also statistically signiﬁ-
cantly induced in the lymphedema group versus controls.
Proteins such as cytotoxic T lymphocyte-associated proteins
are associated with activated T cell function and enhance
TGF-b release by T cells [40]. Leukocyte (or lymphocyte)
speciﬁc protein 1 (LSP1) is a multifunctional protein involved
Table 6. Pathway Analysis for Downregulated Genes in Lymphedema versus Normal Control (SAM, FDR , 0.05)
System Gene Category List
Hits
List
Total
Population
Hits
Population
Total
p-Value Unigene Clusters
GO Biological
Process
Lipid metabolism 8 47 394 10,778 0.001 MM.180189; MM.200373; MM.209300; MM.22505;
MM.259976; MM.3195; MM.4141; MM.61526
Coenzyme and prosthetic
group metabolism
5 47 123 10,078 0.002 MM.19027; MM.27082; MM.30206; MM.61526; MM.6743
Biosynthesis 11 47 874 10,078 0.003 MM.180189; MM.19027; MM.209300; MM.22505;
MM.23951; MM.27082; MM.30206; MM.3845; MM.4141;
MM.61526; MM.6743
Lipid biosynthesis 5 47 152 10,778 0.004 MM.180189; MM.209300; MM.22505; MM.4141; MM.61526
Coenzyme metabolism 4 47 106 10,778 0.010 MM.19027; MM.27082; MM.30206; MM.61526
Steroid biosynthesis 3 47 58 10,778 0.025 MM.22505; MM.4141; MM.61526
Metabolism 31 47 5,384 10,778 0.026 MM.10288; MM.158107; MM.180189; MM.181852;
MM.19027; MM.200373; MM.202360; MM.20521;
MM.20827; MM.209300; MM.220922; MM.22505; MM.23784;
MM.23951; MM.2478; MM.259976; MM.26973; MM.27082;
MM.27227; MM.29352; MM.30206; MM.3195; MM.34173;
MM.35605; MM.3845; MM.4141; MM.42249; MM.5831;
MM.61526; MM.6743; MM.9745
Physiological process 42 47 8,273 10,778 0.028 MM.10288; MM.158107; MM.180189; MM.181852;
MM.19027; MM.200373; MM.202360; MM.20521;
MM.20827; MM.209300; MM.21109; MM.218875;
MM.220922; MM.221298; MM.22505; MM.23784; MM.23951;
MM.2478; MM.259976; MM.2632; MM.26973; MM.27082;
MM.27227; MM.29352; MM.29802; MM.30195; MM.30206;
MM.3195; MM.34173; MM.3433; MM.35605; MM.3845;
MM.38868; MM.4141; MM.42249; MM.4480; MM.46716;
MM.5181; MM.5831; MM.61526; MM.6743; MM.9745
Macromolecule biosynthesis 8 47 731 10,778 0.034 MM.180189; MM.209300; MM.22505; MM.27082; MM.30206;
MM.3845; MM.4141; MM.61526
GO Molecular
Function
Catalytic activity 25 47 4,007 11,303 0.015 MM.10288; MM.158107; MM.180189; MM.200373; MM.200924;
MM.202360; MM.20521; MM.20827; MM.209300; MM.22505;
MM.23784; MM.23951; MM.2478; MM.2632; MM.27082;
MM.27227; MM.29352; MM.29802; MM.29998; MM.30206;
MM.3195; MM.42249; MM.5831; MM.61526; MM.9745
DOI: 10.1371/journal.pmed.0030254.t006
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Inflammatory Manifestations of LymphedemaTable 7. Functional Gene Expression Analysis in Experimental Lymphedema
Category Upregulated Fold
Change
q-Value
(%)
Downregulated Fold
Change
q-Value
(%)
Acute inflammation calgranulin B 22.5:1 2.729 sphingosine kinase 1 0.6:1 3.743
S100 calcium binding protein A11 1.6:1 1.084 gelsolin 0.6:1 1.360
tenascin C 7.8:1 0.913
lipocalin 6.1:1 0.913
stefin A3 4.3:1 0.913
proteoglycan, secretory granule 3.7:1 3.532
L-plastin 2 3.3:1 1.084
follistatin 3.2:1 1.084
procollagen type IV 3.0:1 2.729
arachidonate 5-lipoxygenase activating protein 2.9:1 1.587
stromal cell-derived factor 1 2.5:1 0.913
thymosin, beta 10 2.5:1 1.587
ferritin light chain 1 2.4:1 2.729
legumain 2.4:1 1.084
cathepsin C 2.3:1 1.587
cathepsin Z 2.2:1 1.084
cathepsin H 1.4:1 1.587
cathepsin L 1.5:1 4.279
glutathione peroxidase 1 1.9:1 1.084
platelet factor 4 1.9:1 1.084
lymphocyte specific 1 1.8:1 1.084
Basigin 1.7:1 4.029
thymosin, beta 4 1.7:1 3.238
CD63 antigen 1.5:1 3.730
nuclear factor of kappa light chain gene
enhancer in B cells 1, p105
1.5:1 4.279
peptidylprolyl isomerase B 1.4:1 1.587
prosaposin 1.4:1 3.532
LPS-induced TNF-alpha factor 1.3:1 4.029
nascent polypeptide-associated complex
alpha polypeptide
1.3:1 3.743
Immune Lipocalin 6.1:1 0.913 oxysterol binding protein-like 1A 0.6:1 4.029
cytotoxic T lymphocyte-associated
protein 2 alpha
4.5:1 0.913 villin 2 0.6:1 1.360
Fc receptor, IgE, high affinity I, gamma
polypeptide
4.2:1 0.913 dual specificity phosphatase 14 (MAPK6) 0.7:1 1.084
beta-2 microglobulin 3.9:1 0.913 nuclear factor 2 0.7:1 3.730
lectin, galactose binding, soluble 1 2.9:1 2.276 CD2 antigen binding protein 2 0.8:1 4.903
legumain 2.4:1 1.084 interferon regulatory factor 3 0.8:1 4.029
cathepsin C 2.3:1 1.587
cathepsin Z 2.2:1 1.084
cathepsin H 1.4:1 1.587
cathepsin L 1.5:1 4.279
interferon gamma receptor 2.0:1 0.913
lymphocyte specific 1 1.8:1 1.084
Granulin 1.7:1 1.084
interferon induced transmembrane protein 3-like 1.7:1 1.961
zinc finger protein 100 1.6:1 2.276
lymphocyte antigen 6 complex, locus E 1.6:1 2.729
interferon (alpha and beta) receptor 2 1.5:1 4.279
Complement cascade histocompatibility 2, complement component
factor B
3.1:1 3.238
complement component 1, q subcomponent,
c polypeptide
2.6:1 0.913
calreticulin 2.0:1 1.727
serine (or cysteine) proteinase inhibitor, clade
I (neuroserpin), member 1
2.0:1 3.165
Wound healing and fibrosis Tenascin C 7.8:1 0.913 gelsolin 0.6:1 1.360
Lipocalin 6.1:1 0.913
lysyl oxidase 2.7:1 1.727
Biglycan 2.6:1 3.165
thymosin, beta 10 2.5:1 1.587
procollagen, type V, alpha 2 2.4:1 3.730
fibulin 2 2.0:1 1.084
sorting nexin 5 2.0:1 1.084
platelet factor 4 1.9:1 1.084
actin, alpha 2, smooth muscle, aorta 1.7:1 4.279
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Inflammatory Manifestations of Lymphedemain the regulation of neutrophil motility, chemotaxis, adhe-
sion, and B lymphocyte apoptosis mediated by membrane
immunoglobulin M (mIgM) [41]. Beta-2 microglobulin is a
major histocompatibility complex protein that presents
peptide antigens on cell surfaces for recognition by T cell
receptors. Lipocalin has recently been shown to participate in
the response to bacterial growth [42]. Galactose binding
lectin is a participant in the acute phase response [43].
Granulin is a high-molecular-weight secreted mitogen that is
abundantly expressed in rapidly cycling epithelial cells and in
the immune system [44]. High afﬁnity Fc receptor for IgE is a
key molecule in triggering the allergic reaction; it might be
considered to be a mast-cell-speciﬁc protein. Interferon
gamma has an important role in activating macrophages in
host defenses.
One of the most interesting ﬁndings of our study is that
lymphedema mirrors many of the mechanisms of the
inﬂammatory state, in the absence of a potent inﬂammatory
stimulus. One would not necessarily hypothesize, a priori,
that this would be the case, since the only difference between
lymphedematous animals and the controls (both normals and
surgical shams) was the presence of acute, acquired lymphatic
Table 7. Continued
Category Upregulated Fold
Change
q-Value
(%)
Downregulated Fold
Change
q-Value
(%)
Granulin 1.7:1 1.084
S100 calcium binding protein A11 1.6:1 1.084
Stress response selenoprotein P 2.8:1 2.276 sterol regulatory element binding factor 1 0.5:1 1.727
selenoprotein K 1.3:1 3.743 7-dehydrocholesterol reductase 0.6:1 4.029
selenoprotein W, muscle 1 2.2:1 4.903 DnaJ (Hsp40) homolog, subfamily B, member 1 0.6:1 3.238
DnaJ (Hsp40) homolog, subfamily B, member 5 2.7:1 3.532 malic enzyme, supernatant 0.6:1 3.238
ferritin light chain 1 2.4:1 2.729 methylenetetrahydrofolate dehydrogenase (NAD
þ
dependent), methenyltetrahydrofolate cyclohydrolase
0.6:1 2.729
fibulin 2 2.0:1 1.084 glutathione S-transferase, alpha 4 0.6:1 0.913
glutathione peroxidase 1 1.9:1 1.084 hydroxysteroid (17-beta) dehydrogenase 12 0.7:1 1.360
platelet factor 4 1.9:1 1.084
Carbonyl reductase 2 1.8:1 1.084
glyceraldehyde 3-phosphate dehydrogenase 1:6:1 3.730
heme oxygenase (decycling) 1 1.6:1 0.913
thioredoxin 1 1.6:1 3.730
chaperonin 10 (heat shock protein 1) 1.5:1 3.730
heat shock 70-kDa protein 8 1.5:1 4.029
superoxide dismutase 2 1:5:1 3.165
heat shock 70-kDa protein 2 1.4:1 4.279
heat shock 30-kDa protein 1.3:1 3.743
transaldolase 1 1.3:1 4.279
Angiogenesis thymosin, beta 10 2.5:1 1.587
hypoxia inducible factor 1, alpha subunit 1.9:1 1.961
triosephosphate isomerase 1.9:1 1.727
SRY-box containing gene 18 (SOX18) 1.8:1 4.029
endomucin 1.7:1 1.084
fibroblast growth factor binding protein 1.5:1 2.276
Cytoskeletal caldesmon 1 3.1:1 3.743 gelsolin 0.6:1 1.360
thymosin, beta 10 2.5:1 1.587
actinin, alpha 1 1.8:1 2.729
calcium regulated heat stable protein 1 1.8:1 1.961
t-complex testis expressed 1 1.8:1 3.165
actin, alpha 2, smooth muscle, aorta 1.7:1 4.279
actin, beta, cytoplasmic 1.4:1 3.532
Basigin 1.7:1 4.029
capping protein beta 1 1.7:1 1.961
cofilin 1 1.7:1 4.029
Zyxin 1.6:1 3.743
actin related protein 2/3 complex, subunit 4 1.5:1 1.727
filamin-like 1.5:1 4.903
profilin 1 1.5:1 4.903
transgelin 1.5:1 2.729
ribosomal protein S18 1.2:1 1.961
Wnt pathway Tenascin C 7.8:1 0.913 cadherin 1 0.4:1 0.913
receptor tyrosine kinase-like orphan receptor 2 1.7:1 1.587 Notch gene homolog 1 (Drosophila) 0.5:1 4.029
Adipogenesis fatty acid binding protein 5, epidermal 2.2:1 2.729 diacylglycerol O-acyltransferase 2 0.5.1 1.084
sorting nexin 5 2.0:1 1.084 7-dehydrocholesterol reductase 0.6:1 4.029
esterase 10 1.9:1 1.084 fatty acid synthase 0.6:1 3.238
SRY-box containing gene 18 (SOX18) 1.8:1 4.029 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0.7:1 3.730
coactosin 1.3:1 1.587
DOI: 10.1371/journal.pmed.0030254.t007
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lymphatic stasis induces many of the same mechanisms as
inﬂammatory stimuli. This important observation is novel
and has led us to pursue follow-up investigation intended to
determine the efﬁcacy of inhibitors of the inﬂammatory
pathways in reversing the pathologic responses of the tissues
that are seen in lymphedema.
The apparent absence of lymphatic markers in this tran-
scriptional proﬁle suggests that, in principle, the ﬁndings
might not be speciﬁc for lymphedema. However, in parallel
work performed in the same animal model, we have identiﬁed
several lymphatic markers including, most importantly,
upregulation of VEGF-C (but not VEGF-A) and VEGFR-3.
Therapeutic induction of a lymphangiogenic response
through administration of exogenous, recombinant human
VEGF-C produces both an amelioration of edema and a
downregulation of both of these markers of the lymphatic
vascular response to acquired vascular insufﬁciency (unpub-
lished data). Finally, as seen in Figure 3, LYVE-1 staining
demonstrates speciﬁc lymphatic vascular changes in this
model, including an increase in lymphatic microvascular size
and density, in response to induced lymphatic vascular
disruption. None of the morphological, histochemical, or
gene expression changes referred to here are observed in
animals that are subjected to surgery in the absence of
induction of speciﬁc lymphatic injury (surgical controls), as
described in this paper. Thus, it reasonable to state that the
histological and molecular responses reﬂect lymph stagnation
and not the more nonspeciﬁc responses of wound healing
after surgical injury.
The cellular response to stress is another process that
undergoes statistically signiﬁcant induction during lymph
stagnation. Among the stresses that can trigger this response
are the elaboration of pathophysiological signals such as
cytokines and eicosanoids [45]. The expression of a variety of
heat shock proteins is upregulated in our model [45].
Additional evidence for the oxidative stress in lymphatic
dysfunction is provided by the upregulation of heme oxy-
genase 1 (HO-1) [46]; it is a downstream effector of the potent
anti-inﬂammatory interleukin IL-10 [47].
Upregulation of gene expression related to wound repair,
and importantly, to ﬁbrosis is also prominently seen. During
wound repair granulin promotes granulation and neovascu-
larization, and regulates inﬂammation [48]. The expression of
ﬁbulins is induced in the setting of injury, in response to
various stimuli [49]. Biglycan (BGN) has been implicated in
the regulation of matrix assembly, cellular adhesion, migra-
tion, and TGF-b activity [50]. Endoglin (CD 105) is a type III
TGF-b1 receptor. It modulates the function of TGF-b1b y
binding to and modulating signal transduction by the major
type I and II TGF-b1 receptors. Lysyl oxidase plays a critical
role in the biogenesis of connective tissue matrices. Alpha 2
actin has been identiﬁed as a marker of myoﬁbroblast
differentiation; all ﬁbrocontractive diseases characterized by
ﬁbrosis entail the presence of myoﬁbroblasts [51].
In addition to inﬂammatory/immune and stress responses,
we have observed a gene expression proﬁle that reﬂects
alterations in the angiogenic response. Speciﬁcally, hypoxia
inducible factor 1a has a key role in the cellular response to
hypoxia, including the regulation of genes involved in energy
metabolism, angiogenesis, and apoptosis. Alterations in the
complement and Wnt pathways may also contribute signiﬁ-
cantly to the pathogenesis of the skin response to lymph
stasis.
The observed differences between the lymphedematous
animals and the surgical controls are noteworthy. In the
absence of any observed delay in wound healing, overt
infection, or inﬂammation, the gene expression proﬁle in
Figure 6. qRT-PCR Confirmation of the Results of Microarray Hybridization
The graph represents fold-changes of expression in lymphedema, relative to normal controls, for each of eight representative genes, by microarray
hybridization and qRT-PCR. For MYD88 by microarray and HADH2 by qRT-PCR, the log (gene expression) equaled zero. HADH2, hydroxysteroid (17-beta)
dehydrogenase; 2MMP, matrix metalloproteinase; MYD88, myeloid differentiation primary response gene 88.
DOI: 10.1371/journal.pmed.0030254.g006
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a remarkable induction of whole biological processes via
coordinate upregulation of their component genes. These
observations underscore the interpretation that lymphedema
is a pathological process that is much more complex than a
simple disorder of ﬂuid homeostasis. Indeed, these gene
expression proﬁles superﬁcially resemble those of other
recently elucidated inﬂammatory conditions, such as multiple
sclerosis [31], psoriasis [52], and even atherosclerosis [53,54].
The differentially expressed genes in our study likely arise
from a number of different cell types, including not only the
cellular components of the inﬂammatory response, but also
other involved cell types such as keratinocytes, vascular
endothelial and smooth muscle cells, and ﬁbroblasts. We feel
that it is important to study the gene expression of cells
within the complex cellular milieu of the damaged end organ
in lymphedema, because precisely the genes we are interested
in are those whose transcription results from cell–cell or cell–
interstitial ﬂuid interactions. When one removes cells from
the milieu, there are immediate changes in transcription that
are not reﬂective of the disease state. We are, of course,
interested in deﬁning the cellular compartments that are
expressing speciﬁc genes, and this topic is the focus of
ongoing research in our laboratory that will be published in
the future.
In summary, we have used an animal model of lymphedema
that shares many clinical and histopathological features with
human lymphedema to identify the biological processes and
genes that underlie these features. The fact that inﬂammatory
and immune processes are signiﬁcantly induced suggests that
these observations will provide a useful avenue for the
investigation of novel pharmacologic strategies for lymphatic
dysfunction [2]. This approach is particularly attractive in
light of the observed parallels with other systemic inﬂamma-
tory disease states for which effective therapies already exist.
Ultimately, such therapies must successfully diminish the
impact of the soft tissue ﬁbrosis and adipose deposition that
characterize the late disease [2]; in this regard, it is interesting
to contemplate that expression of several such genes is
detectably altered in this model, long before architectural
evidence of the tissue abnormality is present. This identi-
ﬁcation of such genes provides an avenue for future
investigation and, speciﬁcally, provides early insights into
the elaboration of molecular therapeutics for this disease.
Our purpose here has been to establish an animal model that
can be used in two ways: ﬁrst, to generate new hypotheses
about unsuspected genes and pathways that are involved in
lymphedema and, second, to eventually test potential
pharmacologic and therapeutic interventions for their
efﬁcacy in vivo. We recognize that not all interventions that
show promise in animal models translate effectively into
treatments for human disease, but such in vivo testing is an
essential prerequisite to human application and testing, and
the establishment of a good, relatively inexpensive animal
model is a very important step in allowing more high-
throughput analysis of putative therapeutic interventions.
These studies contribute to our understanding of the patho-
genesis of lymphedema. Further characterization of the genes
and molecular pathways identiﬁed through this effort will
likely provide insights into potential novel strategies for
molecular therapies.
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Editors’ Summary
Background. Lymphedema is the term used to describe the swelling
that can occur after surgery, especially after axillary lymph node
dissection for breast cancer, when the lymph vessels that carry
protein-rich interstitial fluid from the tissues to the heart are damaged.
Lymphedema can be extremely unpleasant and is very hard to treat;
treatments that are currently used include those aimed to help massage
the flow of lymph back to the chest. Lymphedema seems to be more
than just accumulation of lymph, however, as changes also occur in the
tissue surrounding the damaged lymph vessels. Currently, very little is
known at the most basic level about what exactly these changes are,
although they appear to be similar to an inflammatory process. One way
of studying such a disease process in humans is to make an animal
model that mimics the human condition and study the changes that
occur there. For lymphedema, such a model can be made in the mouse
tail by cutting lymph vessels there.
Why Was This Study Done? The authors wanted to look closely at what
happens in the tissues surrounding damaged lymph vessels to try to
understand better what these changes are. They also wanted to study
the movement of the cells that are normally carried in the lymph.
What Did the Researchers Do and Find? The mouse model that the
authors developed closely simulates the characteristics of human
acquired lymphedema. In the mouse tails that had had their lymph
vessels damaged, the authors were able to show that the tails were
swollen compared with those of normal animals and of animals that
hadhad sham (pretend) surgery. In the animals with lymphedema, many
small lymph vessels were seen, as the lymph was unable to flow away
normally. The area affected by the lymphedema had the appearance
often seen in inflamed tissue, and analysis of genes from the same area
to see how active, or ‘‘expressed,’’ they were showed changes that are
often seen in, for example, acute inflammation and wound healing. The
authors also showed that when these animals were injected with
immune cells marked with a light marker, they were less able to remove
the cells from the circulation.
What Do These Findings Mean? These results show that the response
to lymph stagnation is complex, but looks similar to that seen in acute
inflammation. These results and this model may be useful in suggesting,
and at a later date perhaps testing, treatments for lymphedema. One
difference, however, between this mouse model and the condition in
humans is that whereas lymphedema in humans is a rather chronic
condition, here the researchers were only able to look at the changes
over a short period of time. In a related Perspective article, Peter
Carmeliet and colleagues further discuss the clinical relevance of these
findings (http://dx.doi.org/10.1371/journal.pmed.0030264).
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030254.
  The National Cancer Institute has information for patients and health
professionals on lymphedema
  Cancerbackup is a United Kingdom cancer information service with
information on many aspects of cancer, including lymphedema
  The Lymphatic Research Foundation Description has information on
lymphatic system research
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